1
|
St Clair LA, Chan LLY, Boretsky A, Lin B, Spedding M, Perera R. High-Throughput SARS-CoV-2 Antiviral Testing Method Using the Celigo Image Cytometer. J Fluoresc 2024; 34:561-570. [PMID: 37310590 PMCID: PMC10261830 DOI: 10.1007/s10895-023-03289-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2023] [Accepted: 05/27/2023] [Indexed: 06/14/2023]
Abstract
The COVID-19 pandemic has created a worldwide public health crisis that has since resulted in 6.8 million reported deaths. The pandemic prompted the immediate response of researchers around the world to engage in rapid vaccine development, surveillance programs, and antiviral testing, which resulted in the delivery of multiple vaccines and repurposed antiviral drug candidates. However, the emergence of new highly transmissible SARS-CoV-2 variants has renewed the desire for discovering new antiviral drug candidates with high efficacy against the emerging variants of concern. Traditional antiviral testing methods employ the plaque-reduction neutralization tests (PRNTs), plaque assays, or RT-PCR analysis, but each assay can be tedious and time-consuming, requiring 2-3 days to complete the initial antiviral assay in biologically relevant cells, and then 3-4 days to visualize and count plaques in Vero cells, or to complete cell extractions and PCR analysis. In recent years, plate-based image cytometers have demonstrated high-throughput vaccine screening methods, which can be adopted for screening potential antiviral drug candidates. In this work, we developed a high-throughput antiviral testing method employing the Celigo Image Cytometer to investigate the efficacy of antiviral drug candidates on SARS-CoV-2 infectivity using a fluorescent reporter virus and their safety by measuring the cytotoxicity effects on the healthy host cell line using fluorescent viability stains. Compared to traditional methods, the assays defined here eliminated on average 3-4 days from our standard processing time for antiviral testing. Moreover, we were able to utilize human cell lines directly that are not typically amenable to PRNT or plaque assays. The Celigo Image Cytometer can provide an efficient and robust method to rapidly identify potential antiviral drugs to effectively combat the rapidly spreading SARS-CoV-2 virus and its variants during the pandemic.
Collapse
Affiliation(s)
- Laura A St Clair
- Center for Vector-borne Infectious Diseases, Department of Microbiology, Immunology, and Pathology, Colorado State University, CO, 80523, Fort Collins, USA
- Center for Metabolism of Infectious Diseases (C4MInD), Colorado State University, 3185 Rampart Rd, Fort Collins, CO, 80523, USA
| | - Leo Li-Ying Chan
- Department of Advanced Technology R&D, Revvity, 360 Merrimack St. Suite 200, Lawrence, MA, 01843, USA.
| | - Adam Boretsky
- Department of Advanced Technology R&D, Revvity, 360 Merrimack St. Suite 200, Lawrence, MA, 01843, USA
| | - Bo Lin
- Department of Advanced Technology R&D, Revvity, 360 Merrimack St. Suite 200, Lawrence, MA, 01843, USA
| | | | - Rushika Perera
- Center for Vector-borne Infectious Diseases, Department of Microbiology, Immunology, and Pathology, Colorado State University, CO, 80523, Fort Collins, USA.
- Center for Metabolism of Infectious Diseases (C4MInD), Colorado State University, 3185 Rampart Rd, Fort Collins, CO, 80523, USA.
| |
Collapse
|
2
|
Harding SD, Armstrong JF, Faccenda E, Southan C, Alexander SH, Davenport AP, Spedding M, Davies JA. The IUPHAR/BPS Guide to PHARMACOLOGY in 2024. Nucleic Acids Res 2024; 52:D1438-D1449. [PMID: 37897341 PMCID: PMC10767925 DOI: 10.1093/nar/gkad944] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2023] [Revised: 10/09/2023] [Accepted: 10/18/2023] [Indexed: 10/30/2023] Open
Abstract
The IUPHAR/BPS Guide to PHARMACOLOGY (GtoPdb; https://www.guidetopharmacology.org) is an open-access, expert-curated, online database that provides succinct overviews and key references for pharmacological targets and their recommended experimental ligands. It includes over 3039 protein targets and 12 163 ligand molecules, including approved drugs, small molecules, peptides and antibodies. Here, we report recent developments to the resource and describe expansion in content over the six database releases made during the last two years. The database update section of this paper focuses on two areas relating to important global health challenges. The first, SARS-CoV-2 COVID-19, remains a major concern and we describe our efforts to expand the database to include a new family of coronavirus proteins. The second area is antimicrobial resistance, for which we have extended our coverage of antibacterials in partnership with AntibioticDB, a collaboration that has continued through support from GARDP. We discuss other areas of curation and also focus on our external links to resources such as PubChem that bring important synergies to the resources.
Collapse
Affiliation(s)
- Simon D Harding
- Centre for Discovery Brain Science, Deanery of Biomedical Sciences, University of Edinburgh, Edinburgh EH8 9XD, UK
| | - Jane F Armstrong
- Centre for Discovery Brain Science, Deanery of Biomedical Sciences, University of Edinburgh, Edinburgh EH8 9XD, UK
| | - Elena Faccenda
- Centre for Discovery Brain Science, Deanery of Biomedical Sciences, University of Edinburgh, Edinburgh EH8 9XD, UK
| | - Christopher Southan
- Centre for Discovery Brain Science, Deanery of Biomedical Sciences, University of Edinburgh, Edinburgh EH8 9XD, UK
| | - Stephen P H Alexander
- School of Life Sciences, University of Nottingham Medical School, Nottingham NG7 2UH, UK
| | - Anthony P Davenport
- Experimental Medicine and Immunotherapeutics, University of Cambridge, Cambridge CB2 0QQ, UK
| | | | - Jamie A Davies
- Centre for Discovery Brain Science, Deanery of Biomedical Sciences, University of Edinburgh, Edinburgh EH8 9XD, UK
| |
Collapse
|
3
|
Lunghi G, Di Biase E, Carsana EV, Henriques A, Callizot N, Mauri L, Ciampa MG, Mari L, Loberto N, Aureli M, Sonnino S, Spedding M, Chiricozzi E, Fazzari M. GM1 ganglioside exerts protective effects against glutamate-excitotoxicity via its oligosaccharide in wild-type and amyotrophic lateral sclerosis motor neurons. FEBS Open Bio 2023; 13:2324-2341. [PMID: 37885330 PMCID: PMC10699117 DOI: 10.1002/2211-5463.13727] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2023] [Revised: 10/14/2023] [Accepted: 10/25/2023] [Indexed: 10/28/2023] Open
Abstract
Alterations in glycosphingolipid metabolism have been linked to the pathophysiological mechanisms of amyotrophic lateral sclerosis (ALS), a neurodegenerative disease affecting motor neurons. Accordingly, administration of GM1, a sialic acid-containing glycosphingolipid, is protective against neuronal damage and supports neuronal homeostasis, with these effects mediated by its bioactive component, the oligosaccharide head (GM1-OS). Here, we add new evidence to the therapeutic efficacy of GM1 in ALS: Its administration to WT and SOD1G93A motor neurons affected by glutamate-induced excitotoxicity significantly increased neuronal survival and preserved neurite networks, counteracting intracellular protein accumulation and mitochondria impairment. Importantly, the GM1-OS faithfully replicates GM1 activity, emphasizing that even in ALS the protective function of GM1 strictly depends on its pentasaccharide.
Collapse
Affiliation(s)
- Giulia Lunghi
- Department of Medical Biotechnology and Translational MedicineUniversity of MilanoSegrateItaly
| | - Erika Di Biase
- Department of Medical Biotechnology and Translational MedicineUniversity of MilanoSegrateItaly
| | - Emma Veronica Carsana
- Department of Medical Biotechnology and Translational MedicineUniversity of MilanoSegrateItaly
| | | | | | - Laura Mauri
- Department of Medical Biotechnology and Translational MedicineUniversity of MilanoSegrateItaly
| | - Maria Grazia Ciampa
- Department of Medical Biotechnology and Translational MedicineUniversity of MilanoSegrateItaly
| | - Luigi Mari
- Department of ImmunologySt. Jude Children's Research HospitalMemphisTNUSA
| | - Nicoletta Loberto
- Department of Medical Biotechnology and Translational MedicineUniversity of MilanoSegrateItaly
| | - Massimo Aureli
- Department of Medical Biotechnology and Translational MedicineUniversity of MilanoSegrateItaly
| | - Sandro Sonnino
- Department of Medical Biotechnology and Translational MedicineUniversity of MilanoSegrateItaly
| | | | - Elena Chiricozzi
- Department of Medical Biotechnology and Translational MedicineUniversity of MilanoSegrateItaly
| | - Maria Fazzari
- Department of Medical Biotechnology and Translational MedicineUniversity of MilanoSegrateItaly
| |
Collapse
|
4
|
van der Pol KH, Aljofan M, Blin O, Cornel JH, Rongen GA, Woestelandt AG, Spedding M. Drug Repurposing of Generic Drugs: Challenges and the Potential Role for Government. Appl Health Econ Health Policy 2023; 21:831-840. [PMID: 37398987 PMCID: PMC10627937 DOI: 10.1007/s40258-023-00816-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Accepted: 05/17/2023] [Indexed: 07/04/2023]
Abstract
Drug repurposing is the process of identifying a new use for an existing drug or active substance in an indication outside the scope of the original indication. Drug repurposing has important advantages including reduced development time and costs, and potentially large societal healthcare cost savings. However, current generic drug repurposing research faces a number of challenges in obtaining research funds. Furthermore, regardless of the success of a repurposing trial, commercial parties often lack interest in pursuing marketing authorisation for financial reasons, and academic researchers lack the knowledge, time and funding. Therefore, the new indication of a repurposed drug often does not make it 'on label'. We propose a large increase in public funding for generic drug repurposing research, including funds for the marketing authorisation process when a trial is successful, and a reduction in the regulatory burden of the marketing authorisation process for repurposed generic drugs.
Collapse
Affiliation(s)
- Karel H van der Pol
- Department of Internal Medicine, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands
| | - Mohamad Aljofan
- Department of Biomedical Science, Nazarbayev University School of Medicine, Nur-Sultan, Kazakhstan
- National Laboratory Astana, Nazarbayev University, Astana, 010000, Kazakhstan
| | - Olivier Blin
- Institut de Neurosciences des Systèmes, Aix Marseille Université, Inserm UMR 1106, Marseille, France
| | - Jan H Cornel
- Department of Cardiology, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands
- Department of Cardiology, Northwest Clinics, Alkmaar, The Netherlands
| | - Gerard A Rongen
- Department of Internal Medicine, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands.
| | | | | |
Collapse
|
5
|
Alexander SPH, Kelly E, Mathie AA, Peters JA, Veale EL, Armstrong JF, Buneman OP, Faccenda E, Harding SD, Spedding M, Cidlowski JA, Fabbro D, Davenport AP, Striessnig J, Davies JA, Ahlers-Dannen KE, Alqinyah M, Arumugam TV, Bodle C, Dagner JB, Chakravarti B, Choudhuri SP, Druey KM, Fisher RA, Gerber KJ, Hepler JR, Hooks SB, Kantheti HS, Karaj B, Layeghi-Ghalehsoukhteh S, Lee JK, Luo Z, Martemyanov K, Mascarenhas LD, McNabb H, Montañez-Miranda C, Ogujiofor O, Phan H, Roman DL, Shaw V, Sjogren B, Sobey C, Spicer MM, Squires KE, Sutton L, Wendimu M, Wilkie T, Xie K, Zhang Q, Zolghadri Y. The Concise Guide to PHARMACOLOGY 2023/24: Introduction and Other Protein Targets. Br J Pharmacol 2023; 180 Suppl 2:S1-S22. [PMID: 38123153 DOI: 10.1111/bph.16176] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2023] Open
Abstract
The Concise Guide to PHARMACOLOGY 2023/24 is the sixth in this series of biennial publications. The Concise Guide provides concise overviews, mostly in tabular format, of the key properties of approximately 1800 drug targets, and about 6000 interactions with about 3900 ligands. There is an emphasis on selective pharmacology (where available), plus links to the open access knowledgebase source of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties. Although the Concise Guide constitutes almost 500 pages, the material presented is substantially reduced compared to information and links presented on the website. It provides a permanent, citable, point-in-time record that will survive database updates. The full contents of this section can be found at http://onlinelibrary.wiley.com/doi/10.1111/bph.16176. In addition to this overview, in which are identified 'Other protein targets' which fall outside of the subsequent categorisation, there are six areas of focus: G protein-coupled receptors, ion channels, nuclear hormone receptors, catalytic receptors, enzymes and transporters. These are presented with nomenclature guidance and summary information on the best available pharmacological tools, alongside key references and suggestions for further reading. The landscape format of the Concise Guide is designed to facilitate comparison of related targets from material contemporary to mid-2023, and supersedes data presented in the 2021/22, 2019/20, 2017/18, 2015/16 and 2013/14 Concise Guides and previous Guides to Receptors and Channels. It is produced in close conjunction with the Nomenclature and Standards Committee of the International Union of Basic and Clinical Pharmacology (NC-IUPHAR), therefore, providing official IUPHAR classification and nomenclature for human drug targets, where appropriate.
Collapse
Affiliation(s)
- Stephen P H Alexander
- School of Life Sciences, University of Nottingham Medical School, Nottingham, NG7 2UH, UK
| | - Eamonn Kelly
- School of Physiology, Pharmacology and Neuroscience, University of Bristol, Bristol, BS8 1TD, UK
| | - Alistair A Mathie
- School of Allied Health Sciences, University of Suffolk, Ipswich, IP4 1QJ, UK
| | - John A Peters
- Neuroscience Division, Medical Education Institute, Ninewells Hospital and Medical School, University of Dundee, Dundee, DD1 9SY, UK
| | - Emma L Veale
- Medway School of Pharmacy, The Universities of Greenwich and Kent at Medway, Anson Building, Central Avenue, Chatham Maritime, Chatham, Kent, ME4 4TB, UK
| | - Jane F Armstrong
- Centre for Discovery Brain Sciences, University of Edinburgh, Edinburgh, EH8 9XD, UK
| | - O Peter Buneman
- Laboratory for Foundations of Computer Science, School of Informatics, University of Edinburgh, Edinburgh, EH8 9LE, UK
| | - Elena Faccenda
- Centre for Discovery Brain Sciences, University of Edinburgh, Edinburgh, EH8 9XD, UK
| | - Simon D Harding
- Centre for Discovery Brain Sciences, University of Edinburgh, Edinburgh, EH8 9XD, UK
| | | | - John A Cidlowski
- National Institute of Environmental Health Sciences, National Institutes of Health, Department of Health and Human Services, Research Triangle Park, NC, 27709, USA
| | | | | | - Jörg Striessnig
- Pharmacology and Toxicology, Institute of Pharmacy, University of Innsbruck, A-6020, Innsbruck, Austria
| | - Jamie A Davies
- Centre for Discovery Brain Sciences, University of Edinburgh, Edinburgh, EH8 9XD, UK
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | - Zili Luo
- University of Iowa, Iowa City, USA
| | | | | | | | | | - Osita Ogujiofor
- University of Texas Southwestern Medical Center, Dallas, USA
| | - Hoa Phan
- University of Michigan, East Lansing, USA
| | | | | | | | | | | | | | | | | | - Thomas Wilkie
- University of Texas Southwestern Medical Center, Dallas, USA
| | | | | | - Yalda Zolghadri
- University of Texas Southwestern Medical Center, Dallas, USA
| |
Collapse
|
6
|
Armstrong JF, Campo B, Alexander SPH, Arendse LB, Cheng X, Davenport AP, Faccenda E, Fidock DA, Godinez-Macias KP, Harding SD, Kato N, Lee MCS, Luth MR, Mazitschek R, Mittal N, Niles JC, Okombo J, Ottilie S, Pasaje CFA, Probst AS, Rawat M, Rocamora F, Sakata-Kato T, Southan C, Spedding M, Tye MA, Yang T, Zhao N, Davies JA. Advances in Malaria Pharmacology and the online Guide to MALARIA PHARMACOLOGY: IUPHAR Review X. Br J Pharmacol 2023. [PMID: 37197802 DOI: 10.1111/bph.16144] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/20/2022] [Revised: 05/10/2023] [Accepted: 05/14/2023] [Indexed: 05/19/2023] Open
Abstract
Antimalarial drug discovery has until recently been driven by high-throughput phenotypic cellular screening, allowing millions of compounds to be assayed and delivering clinical drug candidates. In this review, we will focus on target-based approaches, describing recent advances in our understanding of druggable targets in the malaria parasite. Targeting multiple stages of the Plasmodium lifecycle, rather than just the clinically symptomatic asexual blood stage, has become a requirement for new antimalarial medicines, and we link pharmacological data clearly to the parasite stages to which it applies. Finally, we highlight the IUPHAR/MMV Guide to MALARIA PHARMACOLOGY, a web resource developed for the malaria research community that provides open and optimized access to published data on malaria pharmacology.
Collapse
Affiliation(s)
- Jane F Armstrong
- Deanery of Biomedical Sciences, The University of Edinburgh, Edinburgh, UK
| | - Brice Campo
- Medicines for Malaria Venture, 20 Route de Pré-Bois, 1215, Geneva, Switzerland
| | | | - Lauren B Arendse
- Drug Discovery and Development Centre (H3D), South African Medical Research Council Drug Discovery and Development Research Unit, Department of Chemistry, and Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Rondebosch, Cape Town, Western Cape, 7701, South Africa
| | - Xiu Cheng
- Global Health Drug Discovery Institute, Bldg 2, Zhongguancun Dongsheng International Science Park, 1 Yongtaizhuang N Rd, Beijing, 100192, China
| | - Anthony P Davenport
- Experimental Medicine and Immunotherapeutics, University of Cambridge, Cambridge, UK
| | - Elena Faccenda
- Deanery of Biomedical Sciences, The University of Edinburgh, Edinburgh, UK
| | - David A Fidock
- Department of Microbiology and Immunology, Columbia University Irving Medical Center, New York, New York, 10032, USA
- Center for Malaria Therapeutics and Antimicrobial Resistance, Division of Infectious Diseases, Department of Medicine, Columbia University Irving Medical Center, New York, New York, 10032, USA
| | - Karla P Godinez-Macias
- Bioinformatics and Systems Biology Graduate Program, University of California, San Diego (UCSD), La Jolla, CA, 92093, USA
| | - Simon D Harding
- Deanery of Biomedical Sciences, The University of Edinburgh, Edinburgh, UK
| | - Nobutaka Kato
- Global Health Drug Discovery Institute, Bldg 2, Zhongguancun Dongsheng International Science Park, 1 Yongtaizhuang N Rd, Beijing, 100192, China
| | - Marcus C S Lee
- Parasites and Microbes Programme, Wellcome Sanger Institute, Hinxton, UK
- Wellcome Centre for Anti-Infectives Research, School of Life Sciences, University of Dundee, Dow Street, Dundee, DD1 5EH, UK
| | - Madeline R Luth
- Department of Pediatrics, University of California San Diego School of Medicine, La Jolla, CA, 92093, USA
| | - Ralph Mazitschek
- Center for Systems Biology, Massachusetts General Hospital, Boston, MA, USA
| | | | - Jacquin C Niles
- Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA
| | - John Okombo
- Department of Immunology and Infectious Diseases, Harvard TH Chan School of Public Health, Boston, USA
| | - Sabine Ottilie
- Department of Pediatrics, University of California San Diego School of Medicine, La Jolla, CA, 92093, USA
- The Scripps Research Institute, Calibr, 11119 North Torrey Pines Road, Suite 100, La Jolla, CA, 92037, USA
| | | | - Alexandra S Probst
- Department of Immunology and Infectious Diseases, Harvard TH Chan School of Public Health, Boston, USA
| | - Mukul Rawat
- Parasites and Microbes Programme, Wellcome Sanger Institute, Hinxton, UK
| | - Frances Rocamora
- Department of Pediatrics, University of California San Diego School of Medicine, La Jolla, CA, 92093, USA
| | - Tomoyo Sakata-Kato
- Global Health Drug Discovery Institute, Bldg 2, Zhongguancun Dongsheng International Science Park, 1 Yongtaizhuang N Rd, Beijing, 100192, China
| | | | | | - Mark A Tye
- Center for Systems Biology, Massachusetts General Hospital, Boston, MA, USA
| | - Tuo Yang
- Department of Pediatrics, School of Medicine, University of California, San Diego, La Jolla, California, 92093, USA
| | - Na Zhao
- Global Health Drug Discovery Institute, Bldg 2, Zhongguancun Dongsheng International Science Park, 1 Yongtaizhuang N Rd, Beijing, 100192, China
| | - Jamie A Davies
- Deanery of Biomedical Sciences, The University of Edinburgh, Edinburgh, UK
| |
Collapse
|
7
|
Connolly CN, Alexander SPH, Davies JA, Spedding M. Environmental pharmacology-Dosing the environment: IUPHAR review 36. Br J Pharmacol 2022; 179:5172-5179. [PMID: 35975296 PMCID: PMC9804906 DOI: 10.1111/bph.15933] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2022] [Revised: 06/22/2022] [Accepted: 07/04/2022] [Indexed: 01/09/2023] Open
Abstract
Pesticide action is predominantly measured as a toxicological outcome, with pharmacological impact of sublethal doses on bystander species left largely undocumented. Likewise, chronic exposure, which often results in responses different from acute administration, has also been understudied. In this article, we propose the application of standard pharmacological principles, already used to establish safe clinical dosing regimens in humans, to the 'dosing of the environment'. These principles include relating the steady state dose of an agent to its beneficial effects (e.g. pest control), while minimising harmful impacts (e.g. off-target bioactivity in beneficial insects). We propose the term 'environmental therapeutic window', analogous to that used in mammalian pharmacology, to guide risk assessment. To make pharmacological terms practically useful to environmental protection, quantitative data on pesticide action need to be made available in a freely accessible database, which should include toxicological and pharmacological impacts on both target and off-target species.
Collapse
Affiliation(s)
| | | | - Jamie A. Davies
- Centre for Discovery Brain SciencesUniversity of EdinburghEdinburghUK
| | | |
Collapse
|
8
|
Spedding M. PL06-04 Pharmacological principles applied to environmental science, pesticides and pollutants. Toxicol Lett 2022. [DOI: 10.1016/j.toxlet.2022.07.049] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
9
|
Wainwright CL, Teixeira MM, Adelson DL, Buenz EJ, David B, Glaser KB, Harata-Lee Y, Howes MJR, Izzo AA, Maffia P, Mayer AM, Mazars C, Newman DJ, Lughadha EN, Pimenta AM, Parra JA, Qu Z, Shen H, Spedding M, Wolfender JL. Corrigendum to “Future directions for the discovery of natural product-derived immunomodulating drugs: An IUPHAR positional review” [Pharmacol. Res. 177 (2022) 106076]. Pharmacol Res 2022; 180:106207. [DOI: 10.1016/j.phrs.2022.106207] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
10
|
Spedding M, Sebban C, Jay TM, Rocher C, Tesolin-Decros B, Chazot P, Schenker E, Szénási G, Lévay GI, Megyeri K, Barkóczy J, Hársing LG, Thomson I, Cunningham MO, Whittington MA, Etherington LA, Lambert JJ, Antoni FA, Gacsályi I. Phenotypical Screening on Neuronal Plasticity in Hippocampal-Prefrontal Cortex Connectivity Reveals an Antipsychotic with a Novel Profile. Cells 2022; 11:cells11071181. [PMID: 35406745 PMCID: PMC8997950 DOI: 10.3390/cells11071181] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2022] [Revised: 03/24/2022] [Accepted: 03/28/2022] [Indexed: 02/01/2023] Open
Abstract
Dysfunction in the hippocampus-prefrontal cortex (H-PFC) circuit is a critical determinant of schizophrenia. Screening of pyridazinone-risperidone hybrids on this circuit revealed EGIS 11150 (S 36549). EGIS 11150 induced theta rhythm in hippocampal slice preparations in the stratum lacunosum molecular area of CA1, which was resistant to atropine and prazosin. EGIS 11150 enhanced H-PFC coherence, and increased the 8−9 Hz theta band of the EEG power spectrum (from 0.002 mg/kg i.p, at >30× lower doses than clozapine, and >100× for olanzapine, risperidone, or haloperidol). EGIS 11150 fully blocked the effects of phencyclidine (PCP) or ketamine on EEG. Inhibition of long-term potentiation (LTP) in H-PFC was blocked by platform stress, but was fully restored by EGIS 11150 (0.01 mg/kg i.p.), whereas clozapine (0.3 mg/kg ip) only partially restored LTP. EGIS 11150 has a unique electrophysiological profile, so phenotypical screening on H-PFC connectivity can reveal novel antipsychotics.
Collapse
Affiliation(s)
- Michael Spedding
- Institut de Recherches Internationales Servier, 92284 Suresnes, France;
- Spedding Research Solutions SAS, 78110 Le Vésinet, France
- Correspondence:
| | - Claude Sebban
- Hôpital Charles Foix, 94205 Ivry-sur-Seine, France; (C.S.); (B.T.-D.)
| | - Thérèse M. Jay
- INSERM UMR_S894, Hôpital Sainte-Anne, Université de Paris V Descartes, 75014 Paris, France; (T.M.J.); (C.R.)
| | - Cyril Rocher
- INSERM UMR_S894, Hôpital Sainte-Anne, Université de Paris V Descartes, 75014 Paris, France; (T.M.J.); (C.R.)
| | | | - Paul Chazot
- Department of Biosciences, University of Durham, Durham DH1 3LE, UK;
| | - Esther Schenker
- Institut de Recherches Internationales Servier, 92284 Suresnes, France;
| | - Gabor Szénási
- Behavioural Pharmacology Laboratory, EGIS Pharmaceuticals Ltd., 1106 Budapest, Hungary; (G.S.); (G.I.L.); (K.M.); (J.B.); (L.G.H.J.); (F.A.A.); (I.G.)
- Institute of Translational Medicine, Semmelweis University, 1085 Budapest, Hungary
| | - György I. Lévay
- Behavioural Pharmacology Laboratory, EGIS Pharmaceuticals Ltd., 1106 Budapest, Hungary; (G.S.); (G.I.L.); (K.M.); (J.B.); (L.G.H.J.); (F.A.A.); (I.G.)
- Gedeon Richter Plc., 1103 Budapest, Hungary
- Department of Morphology and Physiology, Faculty of Health Sciences, Semmelweis University, 1088 Budapest, Hungary
| | - Katalin Megyeri
- Behavioural Pharmacology Laboratory, EGIS Pharmaceuticals Ltd., 1106 Budapest, Hungary; (G.S.); (G.I.L.); (K.M.); (J.B.); (L.G.H.J.); (F.A.A.); (I.G.)
- Hungarian Defence Forces Medical Centre, 1134 Budapest, Hungary
| | - Jozsef Barkóczy
- Behavioural Pharmacology Laboratory, EGIS Pharmaceuticals Ltd., 1106 Budapest, Hungary; (G.S.); (G.I.L.); (K.M.); (J.B.); (L.G.H.J.); (F.A.A.); (I.G.)
| | - Laszlo G. Hársing
- Behavioural Pharmacology Laboratory, EGIS Pharmaceuticals Ltd., 1106 Budapest, Hungary; (G.S.); (G.I.L.); (K.M.); (J.B.); (L.G.H.J.); (F.A.A.); (I.G.)
- Department of Pharmacology and Pharmacotherapy, Semmelweis University, 1085 Budapest, Hungary
| | - Ian Thomson
- Institute of Neurosciences, Faculty of Medical Science, Newcastle University, Newcastle upon Tyne NE2 4HH, UK; (I.T.); (M.O.C.)
| | - Mark O. Cunningham
- Institute of Neurosciences, Faculty of Medical Science, Newcastle University, Newcastle upon Tyne NE2 4HH, UK; (I.T.); (M.O.C.)
- Discipline of Physiology, School of Medicine, Trinity College Dublin, D02 PN40 Dublin, Ireland
| | - Miles A. Whittington
- Deceased, formerly of Hull York Medical School, University of York, Heslington HU6 7RX, UK;
| | - Lori-An Etherington
- Ninewells Hospital and Medical School, University of Dundee, Dundee DD1 9SY, UK; (L.-A.E.); (J.J.L.)
| | - Jeremy J. Lambert
- Ninewells Hospital and Medical School, University of Dundee, Dundee DD1 9SY, UK; (L.-A.E.); (J.J.L.)
| | - Ferenc A. Antoni
- Behavioural Pharmacology Laboratory, EGIS Pharmaceuticals Ltd., 1106 Budapest, Hungary; (G.S.); (G.I.L.); (K.M.); (J.B.); (L.G.H.J.); (F.A.A.); (I.G.)
- Centre for Discovery Brain Sciences, Deanery of Biomedical Sciences, University of Edinburgh, Edinburgh EH8 9XD, UK
| | - Istvan Gacsályi
- Behavioural Pharmacology Laboratory, EGIS Pharmaceuticals Ltd., 1106 Budapest, Hungary; (G.S.); (G.I.L.); (K.M.); (J.B.); (L.G.H.J.); (F.A.A.); (I.G.)
- ATRC Aurigon Toxicological Research Center Ltd., 2120 Dunakeszi, Hungary
| |
Collapse
|
11
|
Wainwright CL, Teixeira MM, Adelson DL, Buenz EJ, David B, Glaser KB, Harata-Lee Y, Howes MJR, Izzo AA, Maffia P, Mayer AM, Mazars C, Newman DJ, Nic Lughadha E, Pimenta AM, Parra JA, Qu Z, Shen H, Spedding M, Wolfender JL. Future Directions for the Discovery of Natural Product-Derived Immunomodulating Drugs. Pharmacol Res 2022; 177:106076. [PMID: 35074524 DOI: 10.1016/j.phrs.2022.106076] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/21/2021] [Accepted: 01/07/2022] [Indexed: 02/06/2023]
Abstract
Drug discovery from natural sources is going through a renaissance, having spent many decades in the shadow of synthetic molecule drug discovery, despite the fact that natural product-derived compounds occupy a much greater chemical space than those created through synthetic chemistry methods. With this new era comes new possibilities, not least the novel targets that have emerged in recent times and the development of state-of-the-art technologies that can be applied to drug discovery from natural sources. Although progress has been made with some immunomodulating drugs, there remains a pressing need for new agents that can be used to treat the wide variety of conditions that arise from disruption, or over-activation, of the immune system; natural products may therefore be key in filling this gap. Recognising that, at present, there is no authoritative article that details the current state-of-the-art of the immunomodulatory activity of natural products, this in-depth review has arisen from a joint effort between the International Union of Basic and Clinical Pharmacology (IUPHAR) Natural Products and Immunopharmacology, with contributions from a Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporation number of world-leading researchers in the field of natural product drug discovery, to provide a "position statement" on what natural products has to offer in the search for new immunomodulatory argents. To this end, we provide a historical look at previous discoveries of naturally occurring immunomodulators, present a picture of the current status of the field and provide insight into the future opportunities and challenges for the discovery of new drugs to treat immune-related diseases.
Collapse
Affiliation(s)
- Cherry L Wainwright
- Centre for Natural Products in Health, Robert Gordon University, Aberdeen, UK.
| | - Mauro M Teixeira
- Department of Biochemistry and Immunology, Universidade Federal de Minas Gerais, Brazil.
| | - David L Adelson
- Molecular & Biomedical Science, University of Adelaide, Australia.
| | - Eric J Buenz
- Nelson Marlborough Institute of Technology, New Zealand.
| | - Bruno David
- Green Mission Pierre Fabre, Pierre Fabre Laboratories, Toulouse, France.
| | - Keith B Glaser
- AbbVie Inc., Integrated Discovery Operations, North Chicago, USA.
| | - Yuka Harata-Lee
- Molecular & Biomedical Science, University of Adelaide, Australia
| | - Melanie-Jayne R Howes
- Royal Botanic Gardens Kew, Richmond, Surrey, UK; Institute of Pharmaceutical Science, Faculty of Life Sciences & Medicine, King's College London, UK.
| | - Angelo A Izzo
- Department of Pharmacy, School of Medicine, University of Naples Federico II, Italy.
| | - Pasquale Maffia
- Department of Pharmacy, School of Medicine, University of Naples Federico II, Italy; Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, UK.
| | - Alejandro Ms Mayer
- Department of Pharmacology, College of Graduate Studies, Midwestern University, IL, USA.
| | - Claire Mazars
- Green Mission Pierre Fabre, Pierre Fabre Laboratories, Toulouse, France.
| | | | | | - Adriano Mc Pimenta
- Laboratory of Animal Venoms and Toxins, Department of Biochemistry and Immunology, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.
| | - John Aa Parra
- Laboratory of Animal Venoms and Toxins, Department of Biochemistry and Immunology, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil
| | - Zhipeng Qu
- Molecular & Biomedical Science, University of Adelaide, Australia
| | - Hanyuan Shen
- Molecular & Biomedical Science, University of Adelaide, Australia
| | | | - Jean-Luc Wolfender
- School of Pharmaceutical Sciences, University of Geneva, Switzerland; Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, Switzerland.
| |
Collapse
|
12
|
Harding SD, Armstrong J, Faccenda E, Southan C, Alexander SPH, Davenport AP, Pawson A, Spedding M, Davies J. The IUPHAR/BPS guide to PHARMACOLOGY in 2022: curating pharmacology for COVID-19, malaria and antibacterials. Nucleic Acids Res 2022; 50:D1282-D1294. [PMID: 34718737 PMCID: PMC8689838 DOI: 10.1093/nar/gkab1010] [Citation(s) in RCA: 78] [Impact Index Per Article: 39.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/15/2021] [Revised: 10/11/2021] [Accepted: 10/12/2021] [Indexed: 11/12/2022] Open
Abstract
The IUPHAR/BPS Guide to PHARMACOLOGY (GtoPdb; www.guidetopharmacology.org) is an open-access, expert-curated database of molecular interactions between ligands and their targets. We describe expansion in content over nine database releases made during the last two years, which has focussed on three main areas of infection. The COVID-19 pandemic continues to have a major impact on health worldwide. GtoPdb has sought to support the wider research community to understand the pharmacology of emerging drug targets for SARS-CoV-2 as well as potential targets in the host to block viral entry and reduce the adverse effects of infection in patients with COVID-19. We describe how the database rapidly evolved to include a new family of Coronavirus proteins. Malaria remains a global threat to half the population of the world. Our database content continues to be enhanced through our collaboration with Medicines for Malaria Venture (MMV) on the IUPHAR/MMV Guide to MALARIA PHARMACOLOGY (www.guidetomalariapharmacology.org). Antibiotic resistance is also a growing threat to global health. In response, we have extended our coverage of antibacterials in partnership with AntibioticDB.
Collapse
Affiliation(s)
- Simon D Harding
- Deanery of Biomedical Sciences, University of Edinburgh, Edinburgh EH8 9XD, UK
| | - Jane F Armstrong
- Deanery of Biomedical Sciences, University of Edinburgh, Edinburgh EH8 9XD, UK
| | - Elena Faccenda
- Deanery of Biomedical Sciences, University of Edinburgh, Edinburgh EH8 9XD, UK
| | - Christopher Southan
- Deanery of Biomedical Sciences, University of Edinburgh, Edinburgh EH8 9XD, UK
| | - Stephen P H Alexander
- School of Life Sciences, University of Nottingham Medical School, Nottingham NG7 2UH, UK
| | - Anthony P Davenport
- Experimental Medicine and Immunotherapeutics, University of Cambridge, Cambridge CB2 0QQ, UK
| | - Adam J Pawson
- Deanery of Biomedical Sciences, University of Edinburgh, Edinburgh EH8 9XD, UK
| | | | - Jamie A Davies
- Deanery of Biomedical Sciences, University of Edinburgh, Edinburgh EH8 9XD, UK
| | | |
Collapse
|
13
|
Spedding M, Marvaud R, Marck A, Delarochelambert Q, Toussaint JF. Aging, VO 2 max, entropy, and COVID-19. Indian J Pharmacol 2022; 54:58-62. [PMID: 35343209 PMCID: PMC9012415 DOI: 10.4103/ijp.ijp_442_21] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
Abstract
The decline in human performance with age at 5000 m, an athletic event requiring high VO2 max, is remarkably precise, and unavoidable, and related to entropy, even at an individual level. Women and men show an identical age-related decline, up to ~100 years old. The precision of the decline shows the limitations for therapy of aging. Mortality incidence for COVID-19 shows a similar relationship. We propose that initial VO2 max has a critical role in COVID sensitivity because of the direct relationship of disease severity with oxygen use, and the parallel decline in aging.
Collapse
Affiliation(s)
- Michael Spedding
- Spedding Research Solutions SAS, 6 Rue Ampère, 78110 Le Vésinet, France
| | - Robin Marvaud
- Spedding Research Solutions SAS, 6 Rue Ampère, 78110 Le Vésinet, France
| | - Adrien Marck
- IRMES (Institut de Recherche bioMédicale et d'Épidémiologie du Sport), INSEP (Institut national du sport, de l'expertise et de la performance), 11, avenue du Tremblay, 75012 Paris, France
| | - Quentin Delarochelambert
- IRMES (Institut de Recherche bioMédicale et d'Épidémiologie du Sport), INSEP (Institut national du sport, de l'expertise et de la performance), 11, avenue du Tremblay, 75012 Paris; Institut de Mathématiques de Bourgogne, UMR 5584 CNRS, Université Bourgogne Franche-Comté, Faculté des Sciences Mirande, 9 avenue Alain Savary, 21000 Dijon; Scientific Department, French Ski Federation, 50 rue des marquisats, 74000 Annecy, France
| | - Jean Francois Toussaint
- IRMES (Institut de Recherche bioMédicale et d'Épidémiologie du Sport), INSEP (Institut national du sport, de l'expertise et de la performance), 11, avenue du Tremblay, 75012 Paris; EA7329, Université de Paris, 12, rue de l'École de Médecine, 75006 Paris; CIMS, Hôtel-Dieu, Assistance Publique - Hôpitaux de Paris, Parvis-Notre-Dame, 75004 Paris, France
| |
Collapse
|
14
|
Alexander SP, Kelly E, Mathie A, Peters JA, Veale EL, Armstrong JF, Faccenda E, Harding SD, Pawson AJ, Southan C, Buneman OP, Cidlowski JA, Christopoulos A, Davenport AP, Fabbro D, Spedding M, Striessnig J, Davies JA, Ahlers-Dannen KE, Alqinyah M, Arumugam TV, Bodle C, Dagner JB, Chakravarti B, Choudhuri SP, Druey KM, Fisher RA, Gerber KJ, Hepler JR, Hooks SB, Kantheti HS, Karaj B, Layeghi-Ghalehsoukhteh S, Lee JK, Luo Z, Martemyanov K, Mascarenhas LD, McNabb H, Montañez-Miranda C, Ogujiofor O, Phan H, Roman DL, Shaw V, Sjogren B, Sobey C, Spicer MM, Squires KE, Sutton L, Wendimu M, Wilkie T, Xie K, Zhang Q, Zolghadri Y. THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: Introduction and Other Protein Targets. Br J Pharmacol 2021; 178 Suppl 1:S1-S26. [PMID: 34529830 PMCID: PMC9513948 DOI: 10.1111/bph.15537] [Citation(s) in RCA: 156] [Impact Index Per Article: 52.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022] Open
Abstract
The Concise Guide to PHARMACOLOGY 2021/22 is the fifth in this series of biennial publications. The Concise Guide provides concise overviews, mostly in tabular format, of the key properties of nearly 1900 human drug targets with an emphasis on selective pharmacology (where available), plus links to the open access knowledgebase source of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties. Although the Concise Guide constitutes over 500 pages, the material presented is substantially reduced compared to information and links presented on the website. It provides a permanent, citable, point‐in‐time record that will survive database updates. The full contents of this section can be found at http://onlinelibrary.wiley.com/doi/bph.15537. In addition to this overview, in which are identified ‘Other protein targets’ which fall outside of the subsequent categorisation, there are six areas of focus: G protein‐coupled receptors, ion channels, nuclear hormone receptors, catalytic receptors, enzymes and transporters. These are presented with nomenclature guidance and summary information on the best available pharmacological tools, alongside key references and suggestions for further reading. The landscape format of the Concise Guide is designed to facilitate comparison of related targets from material contemporary to mid‐2021, and supersedes data presented in the 2019/20, 2017/18, 2015/16 and 2013/14 Concise Guides and previous Guides to Receptors and Channels. It is produced in close conjunction with the Nomenclature and Standards Committee of the International Union of Basic and Clinical Pharmacology (NC‐IUPHAR), therefore, providing official IUPHAR classification and nomenclature for human drug targets, where appropriate.
Collapse
Affiliation(s)
- Stephen Ph Alexander
- School of Life Sciences, University of Nottingham Medical School, Nottingham, NG7 2UH, UK
| | - Eamonn Kelly
- School of Physiology, Pharmacology and Neuroscience, University of Bristol, Bristol, BS8 1TD, UK
| | - Alistair Mathie
- School of Engineering, Arts, Science and Technology, University of Suffolk, Ipswich, IP4 1QJ, UK
| | - John A Peters
- Neuroscience Division, Medical Education Institute, Ninewells Hospital and Medical SchoolUniversity of Dundee, Dundee, DD1 9SY, UK
| | - Emma L Veale
- Medway School of Pharmacy, The Universities of Greenwich and Kent at Medway, Anson Building, Central Avenue, Chatham Maritime, Chatham, Kent, ME4 4TB, UK
| | - Jane F Armstrong
- Centre for Discovery Brain Sciences, University of Edinburgh, Edinburgh, EH8 9XD, UK
| | - Elena Faccenda
- Centre for Discovery Brain Sciences, University of Edinburgh, Edinburgh, EH8 9XD, UK
| | - Simon D Harding
- Centre for Discovery Brain Sciences, University of Edinburgh, Edinburgh, EH8 9XD, UK
| | - Adam J Pawson
- Centre for Discovery Brain Sciences, University of Edinburgh, Edinburgh, EH8 9XD, UK
| | - Christopher Southan
- Centre for Discovery Brain Sciences, University of Edinburgh, Edinburgh, EH8 9XD, UK
| | - O Peter Buneman
- Laboratory for Foundations of Computer Science, School of InformaticsUniversity of Edinburgh, Edinburgh, EH8 9LE, UK
| | - John A Cidlowski
- National Institute of Environmental Health Sciences, National Institutes of Health, Department of Health and Human Services, Research Triangle Park, NC, 27709, USA
| | - Arthur Christopoulos
- Monash Institute of Pharmaceutical oxPharmaceutical Sciences and Department of Pharmacology, Monash University, Parkville, Victoria, 3052, Australia
| | | | | | | | - Jörg Striessnig
- Pharmacology and Toxicology, Institute of Pharmacy, University of Innsbruck, A-6020, Innsbruck, Austria
| | - Jamie A Davies
- Centre for Discovery Brain Sciences, University of Edinburgh, Edinburgh, EH8 9XD, UK
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | - Zili Luo
- University of Iowa, Iowa City, USA
| | | | | | | | | | | | - Hoa Phan
- University of Michigan, East Lansing, USA
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Abstract
In the era of big data, the establishment of a free database, containing all the immune drug targets and associated cell types, is of great value. To this aim, the Guide to Immunopharmacology has been created in a joint effort between the International Union of Basic and Clinical Pharmacology (IUPHAR) and the International Union of Immunological Societies (IUIS). Here we highlight the structure and content of the database, which includes up‐to‐date quantitative information on the fundamental science underlying each immune target. A set of practical examples and tools for data mining are summarized to support immune research into drug discovery and therapeutics.
Collapse
Affiliation(s)
- Simon Milling
- Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK
| | | | - Pasquale Maffia
- Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.,Institute of Cardiovascular and Medical Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.,Department of Pharmacy, University of Naples Federico II, Naples, Italy
| |
Collapse
|
16
|
Alexander SP, Battey J, Benson HE, Benya RV, Bonner TI, Davenport AP, Dhanachandra Singh K, Eguchi S, Harmar A, Holliday N, Jensen RT, Karnik S, Kostenis E, Liew WC, Monaghan AE, Mpamhanga C, Neubig R, Pawson AJ, Pin JP, Sharman JL, Spedding M, Spindel E, Stoddart L, Storjohann L, Thomas WG, Tirupula K, Vanderheyden P. Class A Orphans (version 2020.5) in the IUPHAR/BPS Guide to Pharmacology Database. ACTA ACUST UNITED AC 2020. [DOI: 10.2218/gtopdb/f16/2020.5] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Table 1 lists a number of putative GPCRs identified by NC-IUPHAR [194], for which preliminary evidence for an endogenous ligand has been published, or for which there exists a potential link to a disease, or disorder. These GPCRs have recently been reviewed in detail [150]. The GPCRs in Table 1 are all Class A, rhodopsin-like GPCRs. Class A orphan GPCRs not listed in Table 1 are putative GPCRs with as-yet unidentified endogenous ligands.Table 1: Class A orphan GPCRs with putative endogenous ligands
GPR3
GPR4
GPR6
GPR12
GPR15
GPR17
GPR20
GPR22
GPR26
GPR31
GPR34
GPR35
GPR37
GPR39
GPR50
GPR63
GRP65
GPR68
GPR75
GPR84
GPR87
GPR88
GPR132
GPR149
GPR161
GPR183
LGR4
LGR5
LGR6
MAS1
MRGPRD
MRGPRX1
MRGPRX2
P2RY10
TAAR2
In addition the orphan receptors GPR18, GPR55 and GPR119 which are reported to respond to endogenous agents analogous to the endogenous cannabinoid ligands have been grouped together (GPR18, GPR55 and GPR119).
Collapse
|
17
|
Bouscary A, Quessada C, René F, Spedding M, Turner BJ, Henriques A, Ngo ST, Loeffler JP. Sphingolipids metabolism alteration in the central nervous system: Amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. Semin Cell Dev Biol 2020; 112:82-91. [PMID: 33160824 DOI: 10.1016/j.semcdb.2020.10.008] [Citation(s) in RCA: 22] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2020] [Revised: 10/14/2020] [Accepted: 10/19/2020] [Indexed: 12/11/2022]
Abstract
Sphingolipids are complex lipids. They play a structural role in neurons, but are also involved in regulating cellular communication, and neuronal differentiation and maturation. There is increasing evidence to suggest that dysregulated metabolism of sphingolipids is linked to neurodegenerative processes in amyotrophic lateral sclerosis (ALS), Parkinson's disease and Gaucher's disease. In this review, we provide an overview of the role of sphingolipids in the development and maintenance of the nervous system. We describe the implications of altered metabolism of sphingolipids in the pathophysiology of certain neurodegenerative diseases, with a primary focus on ALS. Finally, we provide an update of potential treatments that could be used to target the metabolism of sphingolipids in neurodegenerative diseases.
Collapse
Affiliation(s)
- Alexandra Bouscary
- Université de Strasbourg, UMR_S 1118, Fédération de Médecine Translationnelle, CRBS, 1 rue Eugène Boeckel, 67000 Strasbourg, France; INSERM, U1118, Mécanismes Centraux et Périphériques de la Neurodégénérescence, CRBS, 1 rue Eugène Boeckel, 67000 Strasbourg, France
| | - Cyril Quessada
- Université de Strasbourg, UMR_S 1118, Fédération de Médecine Translationnelle, CRBS, 1 rue Eugène Boeckel, 67000 Strasbourg, France; INSERM, U1118, Mécanismes Centraux et Périphériques de la Neurodégénérescence, CRBS, 1 rue Eugène Boeckel, 67000 Strasbourg, France
| | - Frédérique René
- Université de Strasbourg, UMR_S 1118, Fédération de Médecine Translationnelle, CRBS, 1 rue Eugène Boeckel, 67000 Strasbourg, France; INSERM, U1118, Mécanismes Centraux et Périphériques de la Neurodégénérescence, CRBS, 1 rue Eugène Boeckel, 67000 Strasbourg, France
| | - Michael Spedding
- Spedding Research Solutions SAS, 6 rue Ampere, 78650 Le Vesinet, France
| | - Bradley J Turner
- The Florey Institute of Neuroscience and Mental Health, University of Melbourne, 30 Royal Parade, Parkville, VIC 3052, Australia
| | | | - Shyuan T Ngo
- Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, Building 75, Cnr College Rd & Cooper Rd, Brisbane city, QLD 4072, Australia; Centre for Clinical Research, The University of Queensland, Building 71/918, Royal Brisbane & Women's Hospital Campus, Herston, QLD 4029, Australia; Queensland Brain Institute Building 79, The University of Queensland, St Lucia, QLD 4072, Australia
| | - Jean-Philippe Loeffler
- Université de Strasbourg, UMR_S 1118, Fédération de Médecine Translationnelle, CRBS, 1 rue Eugène Boeckel, 67000 Strasbourg, France; INSERM, U1118, Mécanismes Centraux et Périphériques de la Neurodégénérescence, CRBS, 1 rue Eugène Boeckel, 67000 Strasbourg, France.
| |
Collapse
|
18
|
Alexander SP, Armstrong JF, Davenport AP, Davies JA, Faccenda E, Harding SD, Levi‐Schaffer F, Maguire JJ, Pawson AJ, Southan C, Spedding M. A rational roadmap for SARS-CoV-2/COVID-19 pharmacotherapeutic research and development: IUPHAR Review 29. Br J Pharmacol 2020; 177:4942-4966. [PMID: 32358833 PMCID: PMC7267163 DOI: 10.1111/bph.15094] [Citation(s) in RCA: 58] [Impact Index Per Article: 14.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2020] [Revised: 04/27/2020] [Accepted: 04/28/2020] [Indexed: 12/13/2022] Open
Abstract
In this review, we identify opportunities for drug discovery in the treatment of COVID-19 and, in so doing, provide a rational roadmap whereby pharmacology and pharmacologists can mitigate against the global pandemic. We assess the scope for targeting key host and viral targets in the mid-term, by first screening these targets against drugs already licensed, an agenda for drug repurposing, which should allow rapid translation to clinical trials. A simultaneous, multi-pronged approach using conventional drug discovery methods aimed at discovering novel chemical and biological means of targeting a short list of host and viral entities which should extend the arsenal of anti-SARS-CoV-2 agents. This longer term strategy would provide a deeper pool of drug choices for future-proofing against acquired drug resistance. Second, there will be further viral threats, which will inevitably evade existing vaccines. This will require a coherent therapeutic strategy which pharmacology and pharmacologists are best placed to provide. LINKED ARTICLES: This article is part of a themed issue on The Pharmacology of COVID-19. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v177.21/issuetoc.
Collapse
Affiliation(s)
- Steve P.H. Alexander
- Chair, Nomenclature and Standards Committee of the International Union of Basic and Clinical Pharmacology (NC‐IUPHAR), School of Life SciencesUniversity of NottinghamNottinghamUK
| | - Jane F. Armstrong
- Curator, Guide to PHARMACOLOGY (GtoPdb), Deanery of Biomedical SciencesUniversity of EdinburghEdinburghUK
| | | | - Jamie A. Davies
- Principal Investigator, Guide to PHARMACOLOGY (GtoPdb), Executive Committee, NC‐IUPHAR, Deanery of Biomedical SciencesUniversity of EdinburghEdinburghUK
| | - Elena Faccenda
- Curator, Guide to PHARMACOLOGY (GtoPdb), Deanery of Biomedical SciencesUniversity of EdinburghEdinburghUK
| | - Simon D. Harding
- Database Developer, Guide to PHARMACOLOGY (GtoPdb), Deanery of Biomedical SciencesUniversity of EdinburghEdinburghUK
| | - Francesca Levi‐Schaffer
- First Vice‐President and Chair of Immunopharmacology Section, International Union of Basic and Clinical Pharmacology (IUPHAR)Hebrew University of JerusalemJerusalemIsrael
| | | | - Adam J. Pawson
- Senior Curator, Guide to PHARMACOLOGY (GtoPdb), Executive Committee, NC‐IUPHAR, Deanery of Biomedical SciencesUniversity of EdinburghEdinburghUK
| | - Christopher Southan
- Deanery of Biomedical SciencesUniversity of EdinburghEdinburghUK
- TW2Informatics LtdGothenburgSweden
| | - Michael Spedding
- Secretary‐General, International Union of Basic and Clinical Pharmacology (IUPHAR) and Spedding Research Solutions SASLe VesinetFrance
| |
Collapse
|
19
|
Hoffmann M, Vander Stichele R, Bates DW, Björklund J, Alexander S, Andersson ML, Auraaen A, Bennie M, Dahl ML, Eiermann B, Hackl W, Hammar T, Hjemdahl P, Koch S, Kunnamo I, Le Louët H, Panagiotis P, Rägo L, Spedding M, Seidling HM, Demner-Fushman D, Gustafsson LL. Guiding principles for the use of knowledge bases and real-world data in clinical decision support systems: report by an international expert workshop at Karolinska Institutet. Expert Rev Clin Pharmacol 2020; 13:925-934. [DOI: 10.1080/17512433.2020.1805314] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Affiliation(s)
- Mikael Hoffmann
- The NEPI Foundation - Swedish Network for Pharmacoepidemiology, Linköping University, Linköping, Sweden
| | - Robert Vander Stichele
- Clinical Pharmacology Research Unit, Heymans Institute of Pharmacology, Ghent University, Ghent, Belgium
| | - David W Bates
- Center for Patient Safety Research and Practice, Division of General Internal Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA
| | | | - Steve Alexander
- School of Life Sciences, University of Nottingham Medical School, Nottingham, UK
| | - Marine L Andersson
- Division of Clinical Pharmacology, Department of Laboratory Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
| | - Ane Auraaen
- Organisation for Economic Cooperation and Development (OECD), Paris, France
| | - Marion Bennie
- Strathclyde Institute of Pharmacy & Biomedical Sciences, University of Strathclyde, Glasgow, UK
| | - Marja-Liisa Dahl
- Division of Clinical Pharmacology, Department of Laboratory Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
| | - Birgit Eiermann
- Division of Clinical Pharmacology, Department of Laboratory Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
| | - Werner Hackl
- Institute of Medical Informatics, UMIT-Private University for Health Sciences, Medical Informatics and Technology, Hall in Tirol, Austria
| | - Tora Hammar
- E-health Institute, Department of Medicine and Optometry, Linnaeus University, Kalmar, Sweden
| | - Paul Hjemdahl
- Clinical Pharmacology Unit, Clinical Epidemiology Division, Department of Medicine, Karolinska Institutet, Stockholm, Sweden
| | - Sabine Koch
- Health Informatics Centre, Department of Learning, Informatics, Management and Ethics, Karolinska Institutet, Stockholm, Sweden
| | - Ilkka Kunnamo
- The Finnish Medical Society Duodecim, Helsinki, Finland
| | - Herve Le Louët
- Council for International Organizations of Medical Sciences (CIOMS), Geneva, Switzerland
| | | | - Lembit Rägo
- Council for International Organizations of Medical Sciences (CIOMS), Geneva, Switzerland
| | - Michael Spedding
- International Union of Basic and Clinical Pharmacology (IUPHAR), Paris, France
| | - Hanna M Seidling
- Department of Clinical Pharmacology and Pharmacoepidemiology, Heidelberg University Hospital, Heidelberg University, Heidelberg, Germany
| | - Dina Demner-Fushman
- National Library of Medicine, National Institutes of Health, HHS, Bethesda, MD, USA
| | - Lars L Gustafsson
- Division of Clinical Pharmacology, Department of Laboratory Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
- Swedish Institute for Drug Informatics (SIDI), Stockholm, Sweden
| |
Collapse
|
20
|
Bouscary A, Quessada C, René F, Spedding M, Henriques A, Ngo S, Loeffler JP. Drug repositioning in neurodegeneration: An overview of the use of ambroxol in neurodegenerative diseases. Eur J Pharmacol 2020; 884:173446. [PMID: 32739173 DOI: 10.1016/j.ejphar.2020.173446] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2020] [Revised: 06/30/2020] [Accepted: 07/29/2020] [Indexed: 12/12/2022]
Abstract
Amyotrophic lateral sclerosis (ALS) is the most common motor neuron disease in adults. While it is primarily characterized by the death of upper and lower motor neurons, there is a significant metabolic component involved in the progression of the disease. Two-thirds of ALS patients have metabolic alterations that are associated with the severity of symptoms. In ALS, as in other neurodegenerative diseases, the metabolism of glycosphingolipids, a class of complex lipids, is strongly dysregulated. We therefore assume that this pathway constitutes an interesting avenue for therapeutic approaches. We have shown that the glucosylceramide degrading enzyme, glucocerebrosidase (GBA) 2 is abnormally increased in the spinal cord of the SOD1G86R mouse model of ALS. Ambroxol, a chaperone molecule that inhibits GBA2, has been shown to have beneficial effects by slowing the development of the disease in SOD1G86R mice. Currently used in clinical trials for Parkinson's and Gaucher disease, ambroxol could be considered as a promising therapeutic treatment for ALS.
Collapse
Affiliation(s)
- Alexandra Bouscary
- INSERM U1118, Mécanismes Centraux et Périphériques de la Neurodégénérescence, Université de Strasbourg, France; Université de Strasbourg, UMR-S 1118, Fédération de Médecine Translationnelle, Strasbourg, France
| | - Cyril Quessada
- INSERM U1118, Mécanismes Centraux et Périphériques de la Neurodégénérescence, Université de Strasbourg, France; Université de Strasbourg, UMR-S 1118, Fédération de Médecine Translationnelle, Strasbourg, France
| | - Frédérique René
- INSERM U1118, Mécanismes Centraux et Périphériques de la Neurodégénérescence, Université de Strasbourg, France; Université de Strasbourg, UMR-S 1118, Fédération de Médecine Translationnelle, Strasbourg, France
| | | | | | - Shyuan Ngo
- Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, Brisbane, QLD, Australia; Centre for Clinical Research, The University of Queensland, Brisbane, QLD, Australia; Queensland Brain Institute, The University of Queensland, Brisbane, QLD, Australia
| | - Jean-Philippe Loeffler
- INSERM U1118, Mécanismes Centraux et Périphériques de la Neurodégénérescence, Université de Strasbourg, France; Université de Strasbourg, UMR-S 1118, Fédération de Médecine Translationnelle, Strasbourg, France.
| |
Collapse
|
21
|
Harding SD, Faccenda E, Southan C, Pawson AJ, Maffia P, Alexander SPH, Davenport AP, Fabbro D, Levi‐Schaffer F, Spedding M, Davies JA. The IUPHAR Guide to Immunopharmacology: connecting immunology and pharmacology. Immunology 2020; 160:10-23. [PMID: 32020584 PMCID: PMC7160657 DOI: 10.1111/imm.13175] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/03/2019] [Revised: 01/17/2020] [Accepted: 01/27/2020] [Indexed: 12/19/2022] Open
Abstract
Given the critical role that the immune system plays in a multitude of diseases, having a clear understanding of the pharmacology of the immune system is crucial to new drug discovery and development. Here we describe the International Union of Basic and Clinical Pharmacology (IUPHAR) Guide to Immunopharmacology (GtoImmuPdb), which connects expert-curated pharmacology with key immunological concepts and aims to put pharmacological data into the hands of immunologists. In the pursuit of new therapeutics, pharmacological databases are a vital resource to researchers through providing accurate information on the fundamental science underlying drug action. This extension to the existing IUPHAR/British Pharmacological Society Guide to Pharmacology supports research into the development of drugs targeted at modulating immune, inflammatory or infectious components of disease. To provide a deeper context for how the resource can support research we show data in GtoImmuPdb relating to a case study on the targeting of vascular inflammation.
Collapse
Affiliation(s)
- Simon D. Harding
- Deanery of Biomedical SciencesUniversity of EdinburghEdinburghUK
| | - Elena Faccenda
- Deanery of Biomedical SciencesUniversity of EdinburghEdinburghUK
| | - Christopher Southan
- Deanery of Biomedical SciencesUniversity of EdinburghEdinburghUK
- Present address:
TW2Informatics LtdGöteborg42166Sweden
| | - Adam J. Pawson
- Deanery of Biomedical SciencesUniversity of EdinburghEdinburghUK
| | - Pasquale Maffia
- Centre for ImmunobiologyInstitute of Infection, Immunity and InflammationCollege of Medical, Veterinary and Life SciencesUniversity of GlasgowGlasgowUK
- Institute of Cardiovascular and Medical SciencesCollege of Medical, Veterinary and Life SciencesUniversity of GlasgowGlasgowUK
- Department of PharmacyUniversity of Naples Federico IINaplesItaly
| | | | | | - Doriano Fabbro
- Cellestia Biotech SABaselSwitzerland
- TargImmune Therapeutics AGBaselSwitzerland
| | | | | | - Jamie A. Davies
- Deanery of Biomedical SciencesUniversity of EdinburghEdinburghUK
| |
Collapse
|
22
|
Maffia P, Mantovani A, Spedding M. Scientists on the Spot: the Guide to Immunopharmacology as a new resource for the cardiovascular community. Cardiovasc Res 2020; 115:e5-e6. [PMID: 30576437 DOI: 10.1093/cvr/cvy296] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- Pasquale Maffia
- Centre for Immunobiology, Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.,Institute of Cardiovascular and Medical Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.,Department of Pharmacy, University of Naples Federico II, Naples, Italy
| | - Alberto Mantovani
- Humanitas Clinical and Research Center, via Manzoni 56, Rozzano, Milan, Italy.,Humanitas University, via Rita Levi Montalcini, Pieve Emanuele, Milan, Italy.,The William Harvey Research Institute, Queen Mary University of London, London, UK
| | - Michael Spedding
- Spedding Research Solutions SAS, 6 Rue Ampere, Le Vesinet, France
| |
Collapse
|
23
|
Armstrong JF, Faccenda E, Harding SD, Pawson AJ, Southan C, Sharman JL, Campo B, Cavanagh DR, Alexander SPH, Davenport AP, Spedding M, Davies JA. The IUPHAR/BPS Guide to PHARMACOLOGY in 2020: extending immunopharmacology content and introducing the IUPHAR/MMV Guide to MALARIA PHARMACOLOGY. Nucleic Acids Res 2020; 48:D1006-D1021. [PMID: 31691834 PMCID: PMC7145572 DOI: 10.1093/nar/gkz951] [Citation(s) in RCA: 93] [Impact Index Per Article: 23.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2019] [Revised: 10/03/2019] [Accepted: 11/04/2019] [Indexed: 12/31/2022] Open
Abstract
The IUPHAR/BPS Guide to PHARMACOLOGY (www.guidetopharmacology.org) is an open-access, expert-curated database of molecular interactions between ligands and their targets. We describe significant updates made over the seven releases during the last two years. The database is notably enhanced through the continued linking of relevant pharmacology with key immunological data types as part of the IUPHAR Guide to IMMUNOPHARMACOLOGY (www.guidetoimmunopharmacology.org) and by a major new extension, the IUPHAR/MMV Guide to Malaria PHARMACOLOGY (www.guidetomalariapharmacology.org). The latter has been constructed in partnership with the Medicines for Malaria Venture, an organization dedicated to identifying, developing and delivering new antimalarial therapies that are both effective and affordable. This is in response to the global challenge of over 200 million cases of malaria and 400 000 deaths worldwide, with the majority in the WHO Africa Region. It provides new pharmacological content, including molecular targets in the malaria parasite, interaction data for ligands with antimalarial activity, and establishes curation of data from screening assays, used routinely in antimalarial drug discovery, against the whole organism. A dedicated portal has been developed to provide quick and focused access to these new data.
Collapse
Affiliation(s)
- Jane F Armstrong
- Deanery of Biomedical Sciences, University of Edinburgh, Edinburgh EH8 9XD, UK
| | - Elena Faccenda
- Deanery of Biomedical Sciences, University of Edinburgh, Edinburgh EH8 9XD, UK
| | - Simon D Harding
- Deanery of Biomedical Sciences, University of Edinburgh, Edinburgh EH8 9XD, UK
| | - Adam J Pawson
- Deanery of Biomedical Sciences, University of Edinburgh, Edinburgh EH8 9XD, UK
| | - Christopher Southan
- Deanery of Biomedical Sciences, University of Edinburgh, Edinburgh EH8 9XD, UK
| | - Joanna L Sharman
- Deanery of Biomedical Sciences, University of Edinburgh, Edinburgh EH8 9XD, UK
| | - Brice Campo
- Medicines for Malaria Venture, Post Box 1826, 1215 Geneva 15, Switzerland
| | - David R Cavanagh
- Institute of Immunology and Infection Research, University of Edinburgh, Edinburgh EH9 3FL, UK
| | - Stephen P H Alexander
- School of Life Sciences, University of Nottingham Medical School, Nottingham NG7 2UH, UK
| | - Anthony P Davenport
- Experimental Medicine and Immunotherapeutics, University of Cambridge, Cambridge CB2 0QQ, UK
| | | | - Jamie A Davies
- Deanery of Biomedical Sciences, University of Edinburgh, Edinburgh EH8 9XD, UK
| | | |
Collapse
|
24
|
Berthelot G, Johnson S, Noirez P, Antero J, Marck A, Desgorces FD, Pifferi F, Carter PA, Spedding M, Manoux AS, Toussaint JF. The age-performance relationship in the general population and strategies to delay age related decline in performance. ACTA ACUST UNITED AC 2019; 77:51. [PMID: 31827790 PMCID: PMC6900856 DOI: 10.1186/s13690-019-0375-8] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/18/2019] [Accepted: 10/27/2019] [Indexed: 02/06/2023]
Abstract
The age-performance relationship describes changes in the organism's structural and functional capabilities over the course of the lifespan. The typical, empirical pattern is an asymmetrical inverted-U shape association with peak capacity occurring early in life. This process is well described in the literature, with an increasing interest in features that characterize this pattern, such as the rate of growth, age of peak performance, and rate of decline with aging. This is usually examined in cohorts of individuals followed over time with repeat assessments of physical or cognitive abilities. This framework ought to be integrated into public health programs, embedding the beneficial (such as physical or cognitive training) or adverse effects (such as chronic diseases or injuries) that respectively sustain or limit capabilities. The maintenance of physical or cognitive performances at older ages would result in both optimal health and promote resistance to disabling conditions and chronic diseases, such as obesity and type 2 diabetes. The causes of accelerated degeneration of health optima are mainly: sedentary and unhealthy lifestyles -including poor nutrition-, exposure to environmental pollutants, and heterogeneity in aging. Better knowledge of optima, compatible with or required for good health, should also allow for establishing ideal conditions for longevity.
Collapse
Affiliation(s)
- Geoffroy Berthelot
- 1IRMES, INSEP, 11 avenue du Tremblay, Paris, 75012 France.,EA 7329, Université de Paris, 12 rue de l'Ecole de Médecine, Paris, 75006 France.,REsearch LAboratory for Interdisciplinary Studies (RELAIS), Paris, France
| | | | - Philippe Noirez
- 1IRMES, INSEP, 11 avenue du Tremblay, Paris, 75012 France.,EA 7329, Université de Paris, 12 rue de l'Ecole de Médecine, Paris, 75006 France
| | - Juliana Antero
- 1IRMES, INSEP, 11 avenue du Tremblay, Paris, 75012 France.,EA 7329, Université de Paris, 12 rue de l'Ecole de Médecine, Paris, 75006 France
| | - Adrien Marck
- 1IRMES, INSEP, 11 avenue du Tremblay, Paris, 75012 France.,EA 7329, Université de Paris, 12 rue de l'Ecole de Médecine, Paris, 75006 France.,REsearch LAboratory for Interdisciplinary Studies (RELAIS), Paris, France
| | - François-Denis Desgorces
- 1IRMES, INSEP, 11 avenue du Tremblay, Paris, 75012 France.,EA 7329, Université de Paris, 12 rue de l'Ecole de Médecine, Paris, 75006 France
| | | | - Patrick A Carter
- 6School of Biological Sciences, Washington State University, Pullman, WA 99164-4236 United States of America
| | - Michael Spedding
- IUPHAR and Spedding Research Solutions SAS, Le Vésinet, 78110 France
| | - Archana Singh Manoux
- 8 Université de Paris, Inserm U1153, Paris, France.,9Department of Epidemiology and Public Health, University College London, London, United Kingdom
| | - Jean-François Toussaint
- 1IRMES, INSEP, 11 avenue du Tremblay, Paris, 75012 France.,EA 7329, Université de Paris, 12 rue de l'Ecole de Médecine, Paris, 75006 France.,CIMS, Hôtel-Dieu, Assistance Publique - Hôpitaux de Paris, Paris, France
| |
Collapse
|
25
|
Alexander SPH, Kelly E, Mathie A, Peters JA, Veale EL, Armstrong JF, Faccenda E, Harding SD, Pawson AJ, Sharman JL, Southan C, Buneman OP, Cidlowski JA, Christopoulos A, Davenport AP, Fabbro D, Spedding M, Striessnig J, Davies JA. THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Introduction and Other Protein Targets. Br J Pharmacol 2019; 176 Suppl 1:S1-S20. [PMID: 31710719 PMCID: PMC6844537 DOI: 10.1111/bph.14747] [Citation(s) in RCA: 257] [Impact Index Per Article: 51.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/03/2022] Open
Abstract
The Concise Guide to PHARMACOLOGY 2019/20 is the fourth in this series of biennial publications. The Concise Guide provides concise overviews of the key properties of nearly 1800 human drug targets with an emphasis on selective pharmacology (where available), plus links to the open access knowledgebase source of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties. Although the Concise Guide represents approximately 400 pages, the material presented is substantially reduced compared to information and links presented on the website. It provides a permanent, citable, point-in-time record that will survive database updates. The full contents of this section can be found at http://onlinelibrary.wiley.com/doi/10.1111/bph.14747. In addition to this overview, in which are identified Other protein targets which fall outside of the subsequent categorisation, there are six areas of focus: G protein-coupled receptors, ion channels, nuclear hormone receptors, catalytic receptors, enzymes and transporters. These are presented with nomenclature guidance and summary information on the best available pharmacological tools, alongside key references and suggestions for further reading. The landscape format of the Concise Guide is designed to facilitate comparison of related targets from material contemporary to mid-2019, and supersedes data presented in the 2017/18, 2015/16 and 2013/14 Concise Guides and previous Guides to Receptors and Channels. It is produced in close conjunction with the International Union of Basic and Clinical Pharmacology Committee on Receptor Nomenclature and Drug Classification (NC-IUPHAR), therefore, providing official IUPHAR classification and nomenclature for human drug targets, where appropriate.
Collapse
Affiliation(s)
- Stephen P H Alexander
- School of Life Sciences, University of Nottingham Medical School, Nottingham, NG7 2UH, UK
| | - Eamonn Kelly
- School of Physiology, Pharmacology and Neuroscience, University of Bristol, Bristol, BS8 1TD, UK
| | - Alistair Mathie
- Medway School of Pharmacy, The Universities of Greenwich and Kent at Medway, Anson Building, Central Avenue, Chatham Maritime, Chatham, Kent, ME4 4TB, UK
| | - John A Peters
- Neuroscience Division, Medical Education Institute, Ninewells Hospital and Medical School, University of Dundee, Dundee, DD1 9SY, UK
| | - Emma L Veale
- Medway School of Pharmacy, The Universities of Greenwich and Kent at Medway, Anson Building, Central Avenue, Chatham Maritime, Chatham, Kent, ME4 4TB, UK
| | - Jane F Armstrong
- Centre for Discovery Brain Sciences, University of Edinburgh, Edinburgh, EH8 9XD, UK
| | - Elena Faccenda
- Centre for Discovery Brain Sciences, University of Edinburgh, Edinburgh, EH8 9XD, UK
| | - Simon D Harding
- Centre for Discovery Brain Sciences, University of Edinburgh, Edinburgh, EH8 9XD, UK
| | - Adam J Pawson
- Centre for Discovery Brain Sciences, University of Edinburgh, Edinburgh, EH8 9XD, UK
| | - Joanna L Sharman
- Centre for Discovery Brain Sciences, University of Edinburgh, Edinburgh, EH8 9XD, UK
| | - Christopher Southan
- Centre for Discovery Brain Sciences, University of Edinburgh, Edinburgh, EH8 9XD, UK
| | - O Peter Buneman
- Laboratory for Foundations of Computer Science, School of Informatics, University of Edinburgh, Edinburgh, EH8 9LE, UK
| | - John A Cidlowski
- National Institute of Environmental Health Sciences, National Institutes of Health, Department of Health and Human Services, Research Triangle Park, NC, 27709, USA
| | - Arthur Christopoulos
- Monash Institute of Pharmaceutical Sciences and Department of Pharmacology, Monash University, Parkville, Victoria, 3052, Australia
| | | | | | | | - Jörg Striessnig
- Pharmacology and Toxicology, Institute of Pharmacy, University of Innsbruck, A-6020, Innsbruck, Austria
| | - Jamie A Davies
- Centre for Discovery Brain Sciences, University of Edinburgh, Edinburgh, EH8 9XD, UK
| |
Collapse
|
26
|
Bouscary A, Quessada C, Mosbach A, Callizot N, Spedding M, Loeffler JP, Henriques A. Ambroxol Hydrochloride Improves Motor Functions and Extends Survival in a Mouse Model of Familial Amyotrophic Lateral Sclerosis. Front Pharmacol 2019; 10:883. [PMID: 31447678 PMCID: PMC6692493 DOI: 10.3389/fphar.2019.00883] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2019] [Accepted: 07/15/2019] [Indexed: 12/12/2022] Open
Abstract
Amyotrophic lateral sclerosis (ALS) is a multifactorial and fatal neurodegenerative disease. Growing evidence connects sphingolipid metabolism to the pathophysiology of ALS. In particular, levels of ceramides, glucosylceramides, and gangliosides are dysregulated in the central nervous system and at the neuromuscular junctions of both animal models and patients. Glucosylceramide is the main precursor of complex glycosphingolipids that is degraded by lysosomal (GBA1) or non-lysosomal (GBA2) glucocerebrosidase. Here, we report that GBA2, but not GBA1, activity is markedly increased in the spinal cord, of SOD1G86R mice, an animal model of familial ALS, even before disease onset. We therefore investigated the effects of ambroxol hydrochloride, a known GBA2 inhibitor, in SOD1G86R mice. A presymptomatic administration of ambroxol hydrochloride, in the drinking water, delayed disease onset, protecting neuromuscular junctions, and the number of functional spinal motor neurons. When administered at disease onset, ambroxol hydrochloride delayed motor function decline, protected neuromuscular junctions, and extended overall survival of the SOD1G86R mice. In addition, ambroxol hydrochloride improved motor recovery and muscle re-innervation after transient sciatic nerve injury in non-transgenic mice and promoted axonal elongation in an in vitro model of motor unit. Our study suggests that ambroxol hydrochloride promotes and protects motor units and improves axonal plasticity, and that this generic compound is a promising drug candidate for ALS.
Collapse
Affiliation(s)
- Alexandra Bouscary
- Université de Strasbourg, UMR_S 1118, Fédération de Médecine Translationnelle, Strasbourg, France.,INSERM, U1118, Mécanismes Centraux et Périphériques de la Neurodégénérescence, Strasbourg, France
| | - Cyril Quessada
- Université de Strasbourg, UMR_S 1118, Fédération de Médecine Translationnelle, Strasbourg, France.,INSERM, U1118, Mécanismes Centraux et Périphériques de la Neurodégénérescence, Strasbourg, France
| | - Althéa Mosbach
- Université de Strasbourg, UMR_S 1118, Fédération de Médecine Translationnelle, Strasbourg, France.,INSERM, U1118, Mécanismes Centraux et Périphériques de la Neurodégénérescence, Strasbourg, France
| | | | | | - Jean-Philippe Loeffler
- Université de Strasbourg, UMR_S 1118, Fédération de Médecine Translationnelle, Strasbourg, France.,INSERM, U1118, Mécanismes Centraux et Périphériques de la Neurodégénérescence, Strasbourg, France
| | - Alexandre Henriques
- Université de Strasbourg, UMR_S 1118, Fédération de Médecine Translationnelle, Strasbourg, France.,INSERM, U1118, Mécanismes Centraux et Périphériques de la Neurodégénérescence, Strasbourg, France.,Spedding Research Solutions SAS, Le Vesinet, France
| |
Collapse
|
27
|
Affiliation(s)
- Michael Spedding
- International Union of Basic and Clinical Pharmacology (IUPHAR), Brentwood, TN 37027, USA
| | - James Barrett
- International Union of Basic and Clinical Pharmacology (IUPHAR), Brentwood, TN 37027, USA
| | - Edward T Morgan
- American Society for Pharmacology and Experimental Therapeutics (ASPET), Rockville, MD 20852, USA
| | - Mary Vore
- American Society for Pharmacology and Experimental Therapeutics (ASPET), Rockville, MD 20852, USA
| | - Dominic Geraghty
- Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT), Hamilton, QLD 4007, Australia
| | - Carl Kirkpatrick
- Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT), Hamilton, QLD 4007, Australia
| | - Ingolf Cascorbi
- International Union of Basic and Clinical Pharmacology (IUPHAR), Brentwood, TN 37027, USA.
| |
Collapse
|
28
|
Marck A, Antero J, Berthelot G, Johnson S, Sedeaud A, Leroy A, Marc A, Spedding M, Di Meglio JM, Toussaint JF. Age-Related Upper Limits in Physical Performances. J Gerontol A Biol Sci Med Sci 2018; 74:591-599. [DOI: 10.1093/gerona/gly165] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2017] [Indexed: 02/04/2023] Open
Affiliation(s)
- Adrien Marck
- Institut de Recherche bio-Médicale et d’Épidémiologie du Sport (IRMES), EA, Institut National du Sport, de l’Expertise et de la Performance (INSEP) and Université Paris Descartes, Sorbonne Paris Cité, Paris
- Laboratoire Matière et Systèmes Complexes (MSC), UMR, Université Paris Diderot and CNRS, Sorbonne Paris cité, Paris
| | - Juliana Antero
- Institut de Recherche bio-Médicale et d’Épidémiologie du Sport (IRMES), EA, Institut National du Sport, de l’Expertise et de la Performance (INSEP) and Université Paris Descartes, Sorbonne Paris Cité, Paris
| | - Geoffroy Berthelot
- Institut de Recherche bio-Médicale et d’Épidémiologie du Sport (IRMES), EA, Institut National du Sport, de l’Expertise et de la Performance (INSEP) and Université Paris Descartes, Sorbonne Paris Cité, Paris
| | - Stacey Johnson
- Institut de Recherche bio-Médicale et d’Épidémiologie du Sport (IRMES), EA, Institut National du Sport, de l’Expertise et de la Performance (INSEP) and Université Paris Descartes, Sorbonne Paris Cité, Paris
| | - Adrien Sedeaud
- Institut de Recherche bio-Médicale et d’Épidémiologie du Sport (IRMES), EA, Institut National du Sport, de l’Expertise et de la Performance (INSEP) and Université Paris Descartes, Sorbonne Paris Cité, Paris
| | - Arthur Leroy
- Institut de Recherche bio-Médicale et d’Épidémiologie du Sport (IRMES), EA, Institut National du Sport, de l’Expertise et de la Performance (INSEP) and Université Paris Descartes, Sorbonne Paris Cité, Paris
| | - Andy Marc
- Institut de Recherche bio-Médicale et d’Épidémiologie du Sport (IRMES), EA, Institut National du Sport, de l’Expertise et de la Performance (INSEP) and Université Paris Descartes, Sorbonne Paris Cité, Paris
| | | | - Jean-Marc Di Meglio
- Laboratoire Matière et Systèmes Complexes (MSC), UMR, Université Paris Diderot and CNRS, Sorbonne Paris cité, Paris
| | - Jean-François Toussaint
- Institut de Recherche bio-Médicale et d’Épidémiologie du Sport (IRMES), EA, Institut National du Sport, de l’Expertise et de la Performance (INSEP) and Université Paris Descartes, Sorbonne Paris Cité, Paris
- Centre d’Investigations en Médecine du Sport (CIMS), Hôtel-Dieu, Assistance Publique—Hôpitaux de Paris, Paris, France
| |
Collapse
|
29
|
Boland B, Yu WH, Corti O, Mollereau B, Henriques A, Bezard E, Pastores GM, Rubinsztein DC, Nixon RA, Duchen MR, Mallucci GR, Kroemer G, Levine B, Eskelinen EL, Mochel F, Spedding M, Louis C, Martin OR, Millan MJ. Promoting the clearance of neurotoxic proteins in neurodegenerative disorders of ageing. Nat Rev Drug Discov 2018; 17:660-688. [PMID: 30116051 DOI: 10.1038/nrd.2018.109] [Citation(s) in RCA: 313] [Impact Index Per Article: 52.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Neurodegenerative disorders of ageing (NDAs) such as Alzheimer disease, Parkinson disease, frontotemporal dementia, Huntington disease and amyotrophic lateral sclerosis represent a major socio-economic challenge in view of their high prevalence yet poor treatment. They are often called 'proteinopathies' owing to the presence of misfolded and aggregated proteins that lose their physiological roles and acquire neurotoxic properties. One reason underlying the accumulation and spread of oligomeric forms of neurotoxic proteins is insufficient clearance by the autophagic-lysosomal network. Several other clearance pathways are also compromised in NDAs: chaperone-mediated autophagy, the ubiquitin-proteasome system, extracellular clearance by proteases and extrusion into the circulation via the blood-brain barrier and glymphatic system. This article focuses on emerging mechanisms for promoting the clearance of neurotoxic proteins, a strategy that may curtail the onset and slow the progression of NDAs.
Collapse
Affiliation(s)
- Barry Boland
- Department of Pharmacology and Therapeutics, University College Cork, Cork, Ireland
| | - Wai Haung Yu
- Department of Pathology and Cell Biology, Taub Institute for Alzheimer's Disease Research, Columbia University, New York, NY, USA
| | - Olga Corti
- ICM Institute for Brain and Spinal Cord, Paris, France
| | | | | | - Erwan Bezard
- CNRS, Institut des Maladies Neurodégénératives, Bordeaux, France
| | - Greg M Pastores
- Department of Metabolic Diseases, Mater Misericordiae University Hospital, Dublin, Ireland
| | - David C Rubinsztein
- Department of Medical Genetics, Cambridge Institute for Medical Research, University of Cambridge and UK Dementia Research Institute, Cambridge Biomedical Campus, Cambridge, UK
| | - Ralph A Nixon
- Center for Dementia Research, Nathan Kline Institute, Orangeburg, NY, USA.,Departments of Psychiatry and Cell Biology, New York University School of Medicine, New York, NY, USA
| | - Michael R Duchen
- UCL Consortium for Mitochondrial Research and Department of Cell and Developmental Biology, University College London, London, UK
| | - Giovanna R Mallucci
- Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK
| | - Guido Kroemer
- Université Paris Descartes/Paris V, Sorbonne Paris Cité, Paris, France.,Université Pierre et Marie Curie/Paris VI, Paris, France.,Equipe 11 labellisée Ligue contre le Cancer, Centre de Recherche des Cordeliers, Paris, France.,INSERM U1138, Paris, France.,Metabolomics and Cell Biology Platforms, Gustave Roussy Comprehensive Cancer Institute, Villejuif, France.,Karolinska Institute, Department of Women's and Children's Health, Karolinska University Hospital, Stockholm, Sweden.,Pôle de Biologie, Hopitâl Européen George Pompidou (AP-HP), Paris, France
| | - Beth Levine
- Center for Autophagy Research, University of Texas Southwestern Medical Center, Dallas, TX, USA.,Howard Hughes Medical Institute, Dallas, TX, USA
| | | | - Fanny Mochel
- INSERM U 1127, Brain and Spine Institute, Paris, France
| | | | - Caroline Louis
- Centre for Therapeutic Innovation in Neuropsychiatry, IDR Servier, 78290 Croissy sur Seine, France
| | - Olivier R Martin
- Université d'Orléans & CNRS, Institut de Chimie Organique et Analytique (ICOA), Orléans, France
| | - Mark J Millan
- Centre for Therapeutic Innovation in Neuropsychiatry, IDR Servier, 78290 Croissy sur Seine, France
| |
Collapse
|
30
|
Harding SD, Sharman JL, Faccenda E, Southan C, Pawson AJ, Ireland S, Gray AJG, Bruce L, Alexander SPH, Anderton S, Bryant C, Davenport AP, Doerig C, Fabbro D, Levi-Schaffer F, Spedding M, Davies JA. The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY. Nucleic Acids Res 2018; 46:D1091-D1106. [PMID: 29149325 PMCID: PMC5753190 DOI: 10.1093/nar/gkx1121] [Citation(s) in RCA: 1437] [Impact Index Per Article: 239.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2017] [Accepted: 10/25/2017] [Indexed: 02/06/2023] Open
Abstract
The IUPHAR/BPS Guide to PHARMACOLOGY (GtoPdb, www.guidetopharmacology.org) and its precursor IUPHAR-DB, have captured expert-curated interactions between targets and ligands from selected papers in pharmacology and drug discovery since 2003. This resource continues to be developed in conjunction with the International Union of Basic and Clinical Pharmacology (IUPHAR) and the British Pharmacological Society (BPS). As previously described, our unique model of content selection and quality control is based on 96 target-class subcommittees comprising 512 scientists collaborating with in-house curators. This update describes content expansion, new features and interoperability improvements introduced in the 10 releases since August 2015. Our relationship matrix now describes ∼9000 ligands, ∼15 000 binding constants, ∼6000 papers and ∼1700 human proteins. As an important addition, we also introduce our newly funded project for the Guide to IMMUNOPHARMACOLOGY (GtoImmuPdb, www.guidetoimmunopharmacology.org). This has been 'forked' from the well-established GtoPdb data model and expanded into new types of data related to the immune system and inflammatory processes. This includes new ligands, targets, pathways, cell types and diseases for which we are recruiting new IUPHAR expert committees. Designed as an immunopharmacological gateway, it also has an emphasis on potential therapeutic interventions.
Collapse
Affiliation(s)
- Simon D Harding
- Deanery of Biomedical Sciences, University of Edinburgh, Edinburgh EH8 9XD, UK
| | - Joanna L Sharman
- Deanery of Biomedical Sciences, University of Edinburgh, Edinburgh EH8 9XD, UK
| | - Elena Faccenda
- Deanery of Biomedical Sciences, University of Edinburgh, Edinburgh EH8 9XD, UK
| | - Chris Southan
- Deanery of Biomedical Sciences, University of Edinburgh, Edinburgh EH8 9XD, UK
| | - Adam J Pawson
- Deanery of Biomedical Sciences, University of Edinburgh, Edinburgh EH8 9XD, UK
| | - Sam Ireland
- Department of Structural & Molecular Biology, University College London, London WC1E 6BT, UK
| | - Alasdair J G Gray
- School of Mathematical and Computer Sciences, Heriot-Watt University, Edinburgh EH14 4AS, UK
| | - Liam Bruce
- School of Mathematical and Computer Sciences, Heriot-Watt University, Edinburgh EH14 4AS, UK
| | - Stephen P H Alexander
- School of Life Sciences, University of Nottingham Medical School, Nottingham NG7 2UH, UK
| | - Stephen Anderton
- MRC Centre for inflammation Research, University of Edinburgh, Edinburgh EH16 4TJ, UK
| | - Clare Bryant
- Department of Veterinary Medicine, University of Cambridge, Cambridge CB3 0ES, UK
| | - Anthony P Davenport
- Experimental Medicine and Immunotherapeutics, University of Cambridge, Cambridge CB2 0QQ, UK
| | - Christian Doerig
- Department of Microbiology, Monash University, Clayton 3800, Australia
| | | | - Francesca Levi-Schaffer
- Pharmacology and Experimental Therapeutics Unit, School of Pharmacy, Institute for Drug Research, Hebrew University of Jerusalem, Jerusalem 9112102, Israel
| | | | - Jamie A Davies
- Deanery of Biomedical Sciences, University of Edinburgh, Edinburgh EH8 9XD, UK
- To whom correspondence should be addressed. Tel: +44 131 650 2999;
| | | |
Collapse
|
31
|
Henriques A, Croixmarie V, Bouscary A, Mosbach A, Keime C, Boursier-Neyret C, Walter B, Spedding M, Loeffler JP. Sphingolipid Metabolism Is Dysregulated at Transcriptomic and Metabolic Levels in the Spinal Cord of an Animal Model of Amyotrophic Lateral Sclerosis. Front Mol Neurosci 2018; 10:433. [PMID: 29354030 PMCID: PMC5758557 DOI: 10.3389/fnmol.2017.00433] [Citation(s) in RCA: 41] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2017] [Accepted: 12/15/2017] [Indexed: 12/11/2022] Open
Abstract
Lipid metabolism is drastically dysregulated in amyotrophic lateral sclerosis and impacts prognosis of patients. Animal models recapitulate alterations in the energy metabolism, including hypermetabolism and severe loss of adipose tissue. To gain insight into the molecular mechanisms underlying disease progression in amyotrophic lateral sclerosis, we have performed RNA-sequencing and lipidomic profiling in spinal cord of symptomatic SOD1G86R mice. Spinal transcriptome of SOD1G86R mice was characterized by differential expression of genes related to immune system, extracellular exosome, and lysosome. Hypothesis-driven identification of metabolites showed that lipids, including sphingomyelin(d18:0/26:1), ceramide(d18:1/22:0), and phosphatidylcholine(o-22:1/20:4) showed profound altered levels. A correlation between disease severity and gene expression or metabolite levels was found for sphingosine, ceramide(d18:1/26:0), Sgpp2, Sphk1, and Ugt8a. Joint-analysis revealed a significant enrichment of glycosphingolipid metabolism in SOD1G86R mice, due to the down-regulation of ceramide, glucosylceramide, and lactosylceramide and the overexpression of genes involved in their recycling in the lysosome. A drug-gene interaction database was interrogated to identify potential drugs able to modulate the dysregulated genes from the signaling pathway. Our results suggest that complex lipids are pivotally changed during the first phase of motor symptoms in an animal model of amyotrophic lateral sclerosis.
Collapse
Affiliation(s)
- Alexandre Henriques
- Université de Strasbourg, UMR_S 1118, Fédération de Médecine Translationnelle, Strasbourg, France.,INSERM, U1118, Mécanismes Centraux et Périphériques de la Neurodégénérescence, Strasbourg, France.,Spedding Research Solutions SAS, Le Vesinet, France
| | | | - Alexandra Bouscary
- Université de Strasbourg, UMR_S 1118, Fédération de Médecine Translationnelle, Strasbourg, France.,INSERM, U1118, Mécanismes Centraux et Périphériques de la Neurodégénérescence, Strasbourg, France
| | - Althéa Mosbach
- Université de Strasbourg, UMR_S 1118, Fédération de Médecine Translationnelle, Strasbourg, France.,INSERM, U1118, Mécanismes Centraux et Périphériques de la Neurodégénérescence, Strasbourg, France
| | - Céline Keime
- Institut de Génétique et de Biologie Moléculaire et Cellulaire, INSERM, U964, CNRS, UMR7104, Université de Strasbourg, Illkirch, France
| | | | | | | | - Jean-Philippe Loeffler
- Université de Strasbourg, UMR_S 1118, Fédération de Médecine Translationnelle, Strasbourg, France.,INSERM, U1118, Mécanismes Centraux et Périphériques de la Neurodégénérescence, Strasbourg, France
| |
Collapse
|
32
|
Alexander SP, Kelly E, Marrion NV, Peters JA, Faccenda E, Harding SD, Pawson AJ, Sharman JL, Southan C, Buneman OP, Cidlowski JA, Christopoulos A, Davenport AP, Fabbro D, Spedding M, Striessnig J, Davies JA. THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Overview. Br J Pharmacol 2017; 174 Suppl 1:S1-S16. [PMID: 29055037 PMCID: PMC5650665 DOI: 10.1111/bph.13882] [Citation(s) in RCA: 253] [Impact Index Per Article: 36.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
Abstract
The Concise Guide to PHARMACOLOGY 2017/18 is the third in this series of biennial publications. This version provides concise overviews of the key properties of nearly 1800 human drug targets with an emphasis on selective pharmacology (where available), plus links to an open access knowledgebase of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties. Although the Concise Guide represents approximately 400 pages, the material presented is substantially reduced compared to information and links presented on the website. It provides a permanent, citable, point-in-time record that will survive database updates. The full contents of this section can be found at http://onlinelibrary.wiley.com/doi/10.1111/bph.13882/full. In addition to this overview, in which are identified 'Other protein targets' which fall outside of the subsequent categorisation, there are eight areas of focus: G protein-coupled receptors, ligand-gated ion channels, voltage-gated ion channels, other ion channels, nuclear hormone receptors, catalytic receptors, enzymes and transporters. These are presented with nomenclature guidance and summary information on the best available pharmacological tools, alongside key references and suggestions for further reading. The landscape format of the Concise Guide is designed to facilitate comparison of related targets from material contemporary to mid-2017, and supersedes data presented in the 2015/16 and 2013/14 Concise Guides and previous Guides to Receptors and Channels. It is produced in close conjunction with the Nomenclature Committee of the Union of Basic and Clinical Pharmacology (NC-IUPHAR), therefore, providing official IUPHAR classification and nomenclature for human drug targets, where appropriate.
Collapse
Affiliation(s)
- Stephen Ph Alexander
- School of Life Sciences, University of Nottingham Medical School, Nottingham, NG7 2UH, UK
| | - Eamonn Kelly
- School of Physiology, Pharmacology and Neuroscience, University of Bristol, Bristol, BS8 1TD, UK
| | - Neil V Marrion
- School of Physiology, Pharmacology and Neuroscience, University of Bristol, Bristol, BS8 1TD, UK
| | - John A Peters
- Neuroscience Division, Medical Education Institute, Ninewells Hospital and Medical School, University of Dundee, Dundee, DD1 9SY, UK
| | - Elena Faccenda
- Centre for Integrative Physiology, University of Edinburgh, Edinburgh, EH8 9XD, UK
| | - Simon D Harding
- Centre for Integrative Physiology, University of Edinburgh, Edinburgh, EH8 9XD, UK
| | - Adam J Pawson
- Centre for Integrative Physiology, University of Edinburgh, Edinburgh, EH8 9XD, UK
| | - Joanna L Sharman
- Centre for Integrative Physiology, University of Edinburgh, Edinburgh, EH8 9XD, UK
| | - Christopher Southan
- Centre for Integrative Physiology, University of Edinburgh, Edinburgh, EH8 9XD, UK
| | - O Peter Buneman
- Laboratory for Foundations of Computer Science, School of Informatics, University of Edinburgh, Edinburgh, EH8 9LE, United Kingdom
| | - John A Cidlowski
- National Institute of Environmental Health Sciences, National Institutes of Health, Department of Health and Human Services, Research Triangle Park, NC 27709, USA
| | - Arthur Christopoulos
- Monash Institute of Pharmaceutical Sciences and Department of Pharmacology, Monash University, Parkville, Victoria 3052, Australia
| | | | | | | | - Jörg Striessnig
- Pharmacology and Toxicology, Institute of Pharmacy, University of Innsbruck, A-6020 Innsbruck, Austria
| | - Jamie A Davies
- Centre for Integrative Physiology, University of Edinburgh, Edinburgh, EH8 9XD, UK
| |
Collapse
|
33
|
Marck A, Antero J, Berthelot G, Saulière G, Jancovici JM, Masson-Delmotte V, Boeuf G, Spedding M, Le Bourg É, Toussaint JF. Are We Reaching the Limits of Homo sapiens? Front Physiol 2017; 8:812. [PMID: 29123486 PMCID: PMC5662890 DOI: 10.3389/fphys.2017.00812] [Citation(s) in RCA: 39] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2017] [Accepted: 10/02/2017] [Indexed: 02/06/2023] Open
Abstract
Echoing scientific and industrial progress, the Twentieth century was an unprecedented period of improvement for human capabilities and performances, with a significant increase in lifespan, adult height, and maximal physiological performance. Analyses of historical data show a major slow down occurring in the most recent years. This triggered large and passionate debates in the academic scene within multiple disciplines; as such an observation could be interpreted as our upper biological limits. Such a new phase of human history may be related to structural and functional limits determined by long term evolutionary constraints, and the interaction between complex systems and their environment. In this interdisciplinary approach, we call into question the validity of subsequent forecasts and projections through innovative and related biomarkers such as sport, lifespan, and height indicators. We set a theoretical framework based on biological and environmental relevance rather than using a typical single-variable forecasting approach. As demonstrated within the article, these new views will have major social, economical, and political implications.
Collapse
Affiliation(s)
- Adrien Marck
- Institut de Recherche bio-Médicale et d'Epidémiologie du Sport (IRMES) EA 7329, Institut National du Sport, de l'Expertise et de la Performance, Université Paris Descartes, Université Sorbonne Paris Cité, Paris, France.,Laboratoire Matière et Systèmes Complexes, UMR 7057 Université Paris Diderot, Centre National de la Recherche Scientifique, Université Sorbonne Paris Cité, Paris, France
| | - Juliana Antero
- Institut de Recherche bio-Médicale et d'Epidémiologie du Sport (IRMES) EA 7329, Institut National du Sport, de l'Expertise et de la Performance, Université Paris Descartes, Université Sorbonne Paris Cité, Paris, France
| | - Geoffroy Berthelot
- Institut de Recherche bio-Médicale et d'Epidémiologie du Sport (IRMES) EA 7329, Institut National du Sport, de l'Expertise et de la Performance, Université Paris Descartes, Université Sorbonne Paris Cité, Paris, France.,Group Adaptation and Prospective, High Council of Public Health, Paris, France.,Research Laboratory for Interdisciplinary Studies, Paris, France
| | - Guillaume Saulière
- Institut de Recherche bio-Médicale et d'Epidémiologie du Sport (IRMES) EA 7329, Institut National du Sport, de l'Expertise et de la Performance, Université Paris Descartes, Université Sorbonne Paris Cité, Paris, France
| | | | - Valérie Masson-Delmotte
- Laboratoire des Sciences du Climat et l'Environnement, Institut Pierre Simon Laplace, CEA-Centre National de la Recherche Scientifique, Université de Versailles Saint-Quentin en Yvelines, Gif-sur-Yvette, France
| | - Gilles Boeuf
- Muséum National d'Histoire Naturelle, Université Pierre et Marie Curie, Sorbonne Universités, Paris, France
| | | | - Éric Le Bourg
- Centre de Recherches sur la Cognition Animale, Centre de Biologie Intégrative, Université de Toulouse, Centre National de la Recherche Scientifique, Université Toulouse III Paul Sabatier, Toulouse, France
| | - Jean-François Toussaint
- Institut de Recherche bio-Médicale et d'Epidémiologie du Sport (IRMES) EA 7329, Institut National du Sport, de l'Expertise et de la Performance, Université Paris Descartes, Université Sorbonne Paris Cité, Paris, France.,Group Adaptation and Prospective, High Council of Public Health, Paris, France.,Centre d'Investigations en Médecine du Sport (CIMS), Hôtel-Dieu de Paris, Assistance Publique - Hôpitaux de Paris, Paris, France
| |
Collapse
|
34
|
Takillah S, Naudé J, Didienne S, Sebban C, Decros B, Schenker E, Spedding M, Mourot A, Mariani J, Faure P. Acute Stress Affects the Expression of Hippocampal Mu Oscillations in an Age-Dependent Manner. Front Aging Neurosci 2017; 9:295. [PMID: 29033825 PMCID: PMC5627040 DOI: 10.3389/fnagi.2017.00295] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/29/2017] [Accepted: 08/29/2017] [Indexed: 12/22/2022] Open
Abstract
Anxiolytic drugs are widely used in the elderly, a population particularly sensitive to stress. Stress, aging and anxiolytics all affect low-frequency oscillations in the hippocampus and prefrontal cortex (PFC) independently, but the interactions between these factors remain unclear. Here, we compared the effects of stress (elevated platform, EP) and anxiolytics (diazepam, DZP) on extracellular field potentials (EFP) in the PFC, parietal cortex and hippocampus (dorsal and ventral parts) of adult (8 months) and aged (18 months) Wistar rats. A potential source of confusion in the experimental studies in rodents comes from locomotion-related theta (6-12 Hz) oscillations, which may overshadow the direct effects of anxiety on low-frequency and especially on the high-amplitude oscillations in the Mu range (7-12 Hz), related to arousal. Animals were restrained to avoid any confound and isolate the direct effects of stress from theta oscillations related to stress-induced locomotion. We identified transient, high-amplitude oscillations in the 7-12 Hz range ("Mu-bursts") in the PFC, parietal cortex and only in the dorsal part of hippocampus. At rest, aged rats displayed more Mu-bursts than adults. Stress acted differently on Mu-bursts depending on age: it increases vs. decreases burst, in adult and aged animals, respectively. In contrast DZP (1 mg/kg) acted the same way in stressed adult and age animal: it decreased the occurrence of Mu-bursts, as well as their co-occurrence. This is consistent with DZP acting as a positive allosteric modulator of GABAA receptors, which globally potentiates inhibition and has anxiolytic effects. Overall, the effect of benzodiazepines on stressed animals was to restore Mu burst activity in adults but to strongly diminish them in aged rats. This work suggests Mu-bursts as a neural marker to study the impact of stress and DZP on age.
Collapse
Affiliation(s)
- Samir Takillah
- Team Neurophysiology and Behavior, Institut de Biologie Paris Seine (IBPS), UMR 8246 Neuroscience Paris Seine (NPS), Sorbonne Universités, Université Pierre et Marie Curie (UPMC), CNRS, INSERM, U1130Paris, France.,Team Brain Development, Repair and Ageing, Institut de Biologie Paris Seine (IBPS), UMR 8256 Biological Adaptation and Ageing (B2A), Sorbonne Universités, Université Pierre et Marie Curie (UPMC), CNRSParis, France.,APHP Hôpital Charles Foix, DHU Fast, Institut de la LongévitéIvry-sur-Seine, France.,Département Neurosciences et Contraintes Opérationnelles, Institut de Recherche Biomédicale des Armées (IRBA), Unité Fatigue et VigilanceBrétigny-sur-Orge, France.,EA7330 VIFASOM, Université Paris DescartesParis, France
| | - Jérémie Naudé
- Team Neurophysiology and Behavior, Institut de Biologie Paris Seine (IBPS), UMR 8246 Neuroscience Paris Seine (NPS), Sorbonne Universités, Université Pierre et Marie Curie (UPMC), CNRS, INSERM, U1130Paris, France
| | - Steve Didienne
- Team Neurophysiology and Behavior, Institut de Biologie Paris Seine (IBPS), UMR 8246 Neuroscience Paris Seine (NPS), Sorbonne Universités, Université Pierre et Marie Curie (UPMC), CNRS, INSERM, U1130Paris, France
| | - Claude Sebban
- Team Brain Development, Repair and Ageing, Institut de Biologie Paris Seine (IBPS), UMR 8256 Biological Adaptation and Ageing (B2A), Sorbonne Universités, Université Pierre et Marie Curie (UPMC), CNRSParis, France.,APHP Hôpital Charles Foix, DHU Fast, Institut de la LongévitéIvry-sur-Seine, France
| | - Brigitte Decros
- Team Brain Development, Repair and Ageing, Institut de Biologie Paris Seine (IBPS), UMR 8256 Biological Adaptation and Ageing (B2A), Sorbonne Universités, Université Pierre et Marie Curie (UPMC), CNRSParis, France.,APHP Hôpital Charles Foix, DHU Fast, Institut de la LongévitéIvry-sur-Seine, France
| | - Esther Schenker
- Neuroscience Drug Discovery Unit, Institut de Recherches ServierCroissy-sur-Seine, France
| | | | - Alexandre Mourot
- Team Neurophysiology and Behavior, Institut de Biologie Paris Seine (IBPS), UMR 8246 Neuroscience Paris Seine (NPS), Sorbonne Universités, Université Pierre et Marie Curie (UPMC), CNRS, INSERM, U1130Paris, France
| | - Jean Mariani
- Team Brain Development, Repair and Ageing, Institut de Biologie Paris Seine (IBPS), UMR 8256 Biological Adaptation and Ageing (B2A), Sorbonne Universités, Université Pierre et Marie Curie (UPMC), CNRSParis, France.,APHP Hôpital Charles Foix, DHU Fast, Institut de la LongévitéIvry-sur-Seine, France
| | - Philippe Faure
- Team Neurophysiology and Behavior, Institut de Biologie Paris Seine (IBPS), UMR 8246 Neuroscience Paris Seine (NPS), Sorbonne Universités, Université Pierre et Marie Curie (UPMC), CNRS, INSERM, U1130Paris, France
| |
Collapse
|
35
|
Spedding M, Schini-Kerth V, Wainwright CL, Du G. I9 IUPHAR: Immunology, metabolism and natural products. Biochem Pharmacol 2017. [DOI: 10.1016/j.bcp.2017.06.055] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
36
|
Etherington LA, Mihalik B, Pálvölgyi A, Ling I, Pallagi K, Kertész S, Varga P, Gunn BG, Brown AR, Livesey MR, Monteiro O, Belelli D, Barkóczy J, Spedding M, Gacsályi I, Antoni FA, Lambert JJ. Selective inhibition of extra-synaptic α5-GABA A receptors by S44819, a new therapeutic agent. Neuropharmacology 2017; 125:353-364. [PMID: 28807671 DOI: 10.1016/j.neuropharm.2017.08.012] [Citation(s) in RCA: 26] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2017] [Revised: 08/07/2017] [Accepted: 08/09/2017] [Indexed: 01/18/2023]
Abstract
In the mammalian central nervous system (CNS) GABAA receptors (GABAARs) mediate neuronal inhibition and are important therapeutic targets. GABAARs are composed of 5 subunits, drawn from 19 proteins, underpinning expression of 20-30 GABAAR subtypes. In the CNS these isoforms are heterogeneously expressed and exhibit distinct physiological and pharmacological properties. We report the discovery of S44819, a novel tricyclic oxazolo-2,3-benzodiazepine-derivative, that selectively inhibits α5-subunit-containing GABAARs (α5-GABAARs). Current α5-GABAAR inhibitors bind to the "benzodiazepine site". However, in HEK293 cells expressing recombinant α5-GABAARs, S44819 had no effect on 3H-flumazenil binding, but displaced the GABAAR agonist 3H-muscimol and competitively inhibited the GABA-induced responses. Importantly, we reveal that the α5-subunit selectivity is uniquely governed by amino acid residues within the α-subunit F-loop, a region associated with GABA binding. In mouse hippocampal CA1 neurons, S44819 enhanced long-term potentiation (LTP), blocked a tonic current mediated by extrasynaptic α5-GABAARs, but had no effect on synaptic GABAARs. In mouse thalamic neurons, S44819 had no effect on the tonic current mediated by δ-GABAARs, or on synaptic (α1β2γ2) GABAARs. In rats, S44819 enhanced object recognition memory and reversed scopolamine-induced impairment of working memory in the eight-arm radial maze. In conclusion, S44819 is a first in class compound that uniquely acts as a potent, competitive, selective antagonist of recombinant and native α5-GABAARs. Consequently, S44819 enhances hippocampal synaptic plasticity and exhibits pro-cognitive efficacy. Given this profile, S44819 may improve cognitive function in neurodegenerative disorders and facilitate post-stroke recovery.
Collapse
Affiliation(s)
- Lori-An Etherington
- Division of Neuroscience, Medical Research Institute, Ninewells Hospital & Medical School, Dundee University, Dundee, DD19SY, Scotland, UK
| | - Balázs Mihalik
- Biotalentum Kft, Gödöllő, Aulich Lajos u. 26, 2100, Hungary
| | | | - István Ling
- Egis Pharmaceuticals PLC, H1106, Budapest, Pf.100, Hungary
| | | | | | - Péter Varga
- Egis Pharmaceuticals PLC, H1106, Budapest, Pf.100, Hungary
| | - Ben G Gunn
- Division of Neuroscience, Medical Research Institute, Ninewells Hospital & Medical School, Dundee University, Dundee, DD19SY, Scotland, UK
| | - Adam R Brown
- Division of Neuroscience, Medical Research Institute, Ninewells Hospital & Medical School, Dundee University, Dundee, DD19SY, Scotland, UK
| | - Matthew R Livesey
- Division of Neuroscience, Medical Research Institute, Ninewells Hospital & Medical School, Dundee University, Dundee, DD19SY, Scotland, UK
| | - Olivia Monteiro
- Division of Neuroscience, Medical Research Institute, Ninewells Hospital & Medical School, Dundee University, Dundee, DD19SY, Scotland, UK
| | - Delia Belelli
- Division of Neuroscience, Medical Research Institute, Ninewells Hospital & Medical School, Dundee University, Dundee, DD19SY, Scotland, UK
| | | | - Michael Spedding
- Institut de Recherches Servier, Croissy-sur-Seine, 78290, France
| | | | | | - Jeremy J Lambert
- Division of Neuroscience, Medical Research Institute, Ninewells Hospital & Medical School, Dundee University, Dundee, DD19SY, Scotland, UK.
| |
Collapse
|
37
|
Henriques A, Huebecker M, Blasco H, Keime C, Andres CR, Corcia P, Priestman DA, Platt FM, Spedding M, Loeffler JP. Inhibition of β-Glucocerebrosidase Activity Preserves Motor Unit Integrity in a Mouse Model of Amyotrophic Lateral Sclerosis. Sci Rep 2017; 7:5235. [PMID: 28701774 PMCID: PMC5507914 DOI: 10.1038/s41598-017-05313-0] [Citation(s) in RCA: 34] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2017] [Accepted: 05/26/2017] [Indexed: 12/11/2022] Open
Abstract
Recent metabolomic reports connect dysregulation of glycosphingolipids, particularly ceramide and glucosylceramide, to neurodegeneration and to motor unit dismantling in amyotrophic lateral sclerosis at late disease stage. We report here altered levels of gangliosides in the cerebrospinal fluid of amyotrophic lateral sclerosis patients in early disease stage. Conduritol B epoxide is an inhibitor of acid beta-glucosidase, and lowers glucosylceramide degradation. Glucosylceramide is the precursor for all of the more complex glycosphingolipids. In SOD1G86R mice, an animal model of amyotrophic lateral sclerosis, conduritol B epoxide preserved ganglioside distribution at the neuromuscular junction, delayed disease onset, improved motor function and preserved motor neurons as well as neuromuscular junctions from degeneration. Conduritol B epoxide mitigated gene dysregulation in the spinal cord and restored the expression of genes involved in signal transduction and axonal elongation. Inhibition of acid beta-glucosidase promoted faster axonal elongation in an in vitro model of neuromuscular junctions and hastened recovery after peripheral nerve injury in wild type mice. Here, we provide evidence that glycosphingolipids play an important role in muscle innervation, which degenerates in amyotrophic lateral sclerosis from the early disease stage. This is a first proof of concept study showing that modulating the catabolism of glucosylceramide may be a therapeutic target for this devastating disease.
Collapse
Affiliation(s)
- Alexandre Henriques
- Université de Strasbourg, UMR_S 1118, Fédération de Médecine Translationnelle, Strasbourg, France
- INSERM, U1118, Mécanismes Centraux et Périphériques de la Neurodégénérescence, Strasbourg, France
- Spedding Research Solutions SAS, Le Vesinet, France
| | | | - Hélène Blasco
- INSERM, Université François-Rabelais, U930, Neurogénétique et Neurométabolomique, Tours, France
- CHRU de Tours, Laboratoire de Biochimie et de Biologie Moléculaire, Tours, France
| | - Céline Keime
- IGBMC (Institut de Génétique et de Biologie Moléculaire et Cellulaire), INSERM, U964, CNRS, UMR7104, Université de Strasbourg, 67404, Illkirch, France
| | - Christian R Andres
- INSERM, Université François-Rabelais, U930, Neurogénétique et Neurométabolomique, Tours, France
- CHRU de Tours, Laboratoire de Biochimie et de Biologie Moléculaire, Tours, France
| | - Philippe Corcia
- INSERM, Université François-Rabelais, U930, Neurogénétique et Neurométabolomique, Tours, France
- CHRU de Tours, Centre SLA, Tours, France
| | | | - Frances M Platt
- Department of Pharmacology, University of Oxford, Oxford, UK
| | | | - Jean-Philippe Loeffler
- Université de Strasbourg, UMR_S 1118, Fédération de Médecine Translationnelle, Strasbourg, France.
- INSERM, U1118, Mécanismes Centraux et Périphériques de la Neurodégénérescence, Strasbourg, France.
| |
Collapse
|
38
|
Caraci F, Enna SJ, Zohar J, Racagni G, Zalsman G, van den Brink W, Kasper S, Koob GF, Pariante CM, Piazza PV, Yamada K, Spedding M, Drago F. A new nomenclature for classifying psychotropic drugs. Br J Clin Pharmacol 2017; 83:1614-1616. [PMID: 28401576 DOI: 10.1111/bcp.13302] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2016] [Revised: 03/06/2017] [Accepted: 03/26/2017] [Indexed: 12/01/2022] Open
Abstract
The Neuroscience-based Nomenclature (NbN) for psychotropic drugs was developed as an alternative to the current Anatomical Therapeutic Chemical (ATC) indication-based classification in order to provide more precise designations for this drug class. The ATC nomenclature for psychotherapeutics is limited in that it fails to specify either pharmacological domains or mechanism of action and also does not describe all the potential uses of a particular agent. The disconnect between the drug classification and its clinical use is not very useful for scientific purposes and is confusing for patients and caregivers, often leading to a misunderstanding of the intended effects of the prescribed medication and, most importantly, to low treatment adherence. The NbN classifies psychopharmacological agents on the basis of contemporary scientific information on their pharmacology and mechanisms of action so as to provide physicians clear alternatives when selecting or altering therapeutic regimens. The classification of each psychotropic drug includes four additional dimensions: approved indications; efficacy and side effects; practical note; neurobiology. By emphasizing the pharmacology and the molecular mechanism of action, NbN provides a vehicle for clinicians and basic scientists to improve the understanding and clinical use of this important drug class.
Collapse
Affiliation(s)
- Filippo Caraci
- Department of Drug Sciences, University of Catania, Catania, Italy.,Oasi Institute for Research on Mental Retardation and Brain Aging (IRCCS), Troina, Italy
| | - Sam J Enna
- Department of Molecular and Integrative Physiology, Department of Pharmacology, Toxicology and Therapeutics, University of Kansas Medical Center, Kansas City, Kansas, USA
| | - Joseph Zohar
- Department of Psychiatry, Sheba Medical Center and Sackler School of Medicine, Tel Aviv University, Tel Hashomer, Israel
| | - Giorgio Racagni
- Department of Pharmacological and Biomolecolar Sciences, University of Milan, Milan, Italy
| | - Gil Zalsman
- Geha Mental Health Center and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.,Division of Molecular Imaging and Neuropathology, Department of Psychiatry, Columbia University and New York State Psychiatric Institute, New York, New York, USA
| | - Wim van den Brink
- Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
| | - Siegfried Kasper
- Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.,Department of Psychiatry and Psychotherapy, Medical University of Vienna, Waehringer Guertel, 18-201090, Vienna, Austria
| | - George F Koob
- Neurobiology of Addiction Section, Integrative Neuroscience Research Branch, National Institute on Drug Abuse, Baltimore, Maryland, USA.,National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, Maryland, USA
| | - Carmine M Pariante
- Department of Psychological Medicine, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK
| | - Pier Vincenzo Piazza
- Inserm U1215, Neurocentre Magendie, Physiopathology of Addiction Group, Bordeaux, France.,Université de Bordeaux, Bordeaux, France
| | - Kiyofumi Yamada
- Department of Neuropsychopharmacology and Hospital Pharmacy, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, Aichi, Japan
| | - Michael Spedding
- Spedding Research Solutions SAS, 6 Rue Ampere, Le Vesinet, 78110, France
| | - Filippo Drago
- Department of Biomedical and Biotechnological Sciences, University of Catania, Catania, Italy.,Unifarm Research Centre, Catania, Italy
| |
Collapse
|
39
|
Rame M, Caudal D, Schenker E, Svenningsson P, Spedding M, Jay TM, Godsil BP. Clozapine counteracts a ketamine-induced depression of hippocampal-prefrontal neuroplasticity and alters signaling pathway phosphorylation. PLoS One 2017; 12:e0177036. [PMID: 28472198 PMCID: PMC5417651 DOI: 10.1371/journal.pone.0177036] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2017] [Accepted: 04/20/2017] [Indexed: 01/01/2023] Open
Abstract
Single sub-anesthetic doses of ketamine can exacerbate the symptoms of patients diagnosed with schizophrenia, yet similar ketamine treatments rapidly reduce depressive symptoms in major depression. Acute doses of the atypical antipsychotic drug clozapine have also been shown to counteract ketamine-induced psychotic effects. In the interest of understanding whether these drug effects could be modeled with alterations in neuroplasticity, we examined the impact of acutely-administered ketamine and clozapine on in vivo long-term potentiation (LTP) in the rat’s hippocampus-to-prefrontal cortex (H-PFC) pathway. We found that a low dose of ketamine depressed H-PFC LTP, whereas animals that were co-administrated the two drugs displayed LTP that was similar to a saline-treated control. To address which signaling molecules might mediate such effects, we also examined phosphorylation and total protein levels of GSK3β, GluA1, TrkB, ERK, and mTOR in prefrontal and hippocampal sub-regions. Among the statistically significant effects that were detected (a) both ketamine and clozapine increased the phosphorylation of Ser9-GSK3β throughout the prefrontal cortex and of Ser2481-mTOR in the dorsal hippocampus (DH), (b) clozapine increased the phosphorylation of Ser831-GluA1 throughout the prefrontal cortex and of Ser845-GluA1 in the ventral hippocampus, (c) ketamine treatment increased the phosphorylation of Thr202/Tyr204-ERK in the medial PFC (mPFC), and (d) clozapine treatment was associated with decreases in the phosphorylation of Tyr705-TrkB in the DH and of Try816-TrkB in the mPFC. Further analyses involving phosphorylation effect sizes also suggested Ser831-GluA1 in the PFC displayed the highest degree of clozapine-responsivity relative to ketamine. These results provide evidence for how ketamine and clozapine treatments affect neuroplasticity and signaling pathways in the stress-sensitive H-PFC network. They also demonstrate the potential relevance of H-PFC pathway neuroplasticity for modeling ketamine-clozapine interactions in regards to psychosis.
Collapse
Affiliation(s)
- Marion Rame
- Laboratoire de Physiopathologie des Maladies Psychiatriques, UMR_S894 Inserm, Centre de Psychiatrie et Neurosciences, Paris, France
- Université Paris Descartes, Sorbonne Paris Cité, Paris, France
| | - Dorian Caudal
- Department of Clinical Neuroscience, Center for Molecular Medicine, Karolinska Institute, Stockholm, Sweden
| | | | - Per Svenningsson
- Department of Clinical Neuroscience, Center for Molecular Medicine, Karolinska Institute, Stockholm, Sweden
| | - Michael Spedding
- Institut de Recherches Servier, Croissy-sur-Seine, France
- Spedding Research Solutions SAS, Le Vesinet, France
| | - Thérèse M. Jay
- Laboratoire de Physiopathologie des Maladies Psychiatriques, UMR_S894 Inserm, Centre de Psychiatrie et Neurosciences, Paris, France
- Université Paris Descartes, Sorbonne Paris Cité, Paris, France
| | - Bill P. Godsil
- Laboratoire de Physiopathologie des Maladies Psychiatriques, UMR_S894 Inserm, Centre de Psychiatrie et Neurosciences, Paris, France
- Université Paris Descartes, Sorbonne Paris Cité, Paris, France
- * E-mail:
| |
Collapse
|
40
|
Głombik K, Stachowicz A, Olszanecki R, Ślusarczyk J, Trojan E, Lasoń W, Kubera M, Budziszewska B, Spedding M, Basta-Kaim A. The effect of chronic tianeptine administration on the brain mitochondria: direct links with an animal model of depression. Mol Neurobiol 2016; 53:7351-7362. [PMID: 26934888 PMCID: PMC5104776 DOI: 10.1007/s12035-016-9807-4] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2015] [Accepted: 02/18/2016] [Indexed: 11/06/2022]
Abstract
A growing body of evidence has focused on the impact of mitochondrial disturbances in the development of depression, but little data exist regarding the effects of chronic administration of antidepressant drugs on the brain's mitochondrial protein profile. The aim of this study was to investigate the impact of chronic treatment with an atypical antidepressant drug-tianeptine-on the mitochondria-enriched subproteome profile in the hippocampus and the frontal cortex of 3-month-old male rats following a prenatal stress procedure. Rats that were exposed to a prenatal stress procedure displayed depressive- and anxiety-like disturbances based on the elevated plus-maze and Porsolt tests. Moreover, two-dimensional electrophoresis coupled with mass spectrometry showed structure-dependent mitoproteome changes in brains of prenatally stressed rats after chronic tianeptine administration. A component of 2-oxoglutarate and succinate flavoprotein subunit dehydrogenases, isocitrate subunit alpha, was upregulated in the hippocampus. In the frontal cortex, there was a striking increase in the expression of glutamate dehydrogenase and cytochrome bc1 complex subunit 2. These findings suggest that mitochondria are underappreciated targets for therapeutic interventions, and mitochondrial function may be crucial for the effective treatment of stress-related diseases.
Collapse
Affiliation(s)
- Katarzyna Głombik
- Department of Experimental Neuroendocrinology, Institute of Pharmacology, Polish Academy of Sciences, 12 Smętna St, 31-343, Kraków, Poland
| | - Aneta Stachowicz
- Chair of Pharmacology, Jagiellonian University Medical College, 16 Grzegórzecka Street, 31-531, Kraków, Poland
| | - Rafał Olszanecki
- Chair of Pharmacology, Jagiellonian University Medical College, 16 Grzegórzecka Street, 31-531, Kraków, Poland
| | - Joanna Ślusarczyk
- Department of Experimental Neuroendocrinology, Institute of Pharmacology, Polish Academy of Sciences, 12 Smętna St, 31-343, Kraków, Poland
| | - Ewa Trojan
- Department of Experimental Neuroendocrinology, Institute of Pharmacology, Polish Academy of Sciences, 12 Smętna St, 31-343, Kraków, Poland
| | - Władysław Lasoń
- Department of Experimental Neuroendocrinology, Institute of Pharmacology, Polish Academy of Sciences, 12 Smętna St, 31-343, Kraków, Poland
| | - Marta Kubera
- Department of Experimental Neuroendocrinology, Institute of Pharmacology, Polish Academy of Sciences, 12 Smętna St, 31-343, Kraków, Poland
| | - Bogusława Budziszewska
- Department of Experimental Neuroendocrinology, Institute of Pharmacology, Polish Academy of Sciences, 12 Smętna St, 31-343, Kraków, Poland
| | - Michael Spedding
- Physiopathogie des Maladies Psychiatriques, INSERM UMR_S 894, Centre de Psychiatrie et Neurosciences, 2ter rue d'Alesia, 75014, Paris, France
| | - Agnieszka Basta-Kaim
- Department of Experimental Neuroendocrinology, Institute of Pharmacology, Polish Academy of Sciences, 12 Smętna St, 31-343, Kraków, Poland.
| |
Collapse
|
41
|
Artigas F, Schenker E, Celada P, Spedding M, Lladó-Pelfort L, Jurado N, Núñez M, Santana N, Troyano-Rodriguez E, Riga MS, van den Munkhof H, Castañé A, Shaban H, Jay TM, Tripathi A, Godsil BP, Sebban C, Mariani J, Faure P, Takkilah S, Hughes ZA, Siok CJ, Hajos M, Wicke K, Gass N, Weber-Fahr W, Sartorius A, Becker R, Didriksen M, Bastlund JF, Tricklebank M, Risterucci C, Meyer-Lindenberg A, Schwarz AJ. Defining the brain circuits involved in psychiatric disorders: IMI-NEWMEDS. Nat Rev Drug Discov 2016; 16:1-2. [DOI: 10.1038/nrd.2016.205] [Citation(s) in RCA: 26] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
42
|
Spedding M, Kumar D, Patel B, Gupta YK. Alliance between the International Union of Basic and Clinical Pharmacology and the Indian Pharmacological Society for Health, Education, Drug Discovery, and Development in India. Indian J Pharmacol 2016; 48:229-31. [PMID: 27298488 PMCID: PMC4899990 DOI: 10.4103/0253-7613.182873] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
Affiliation(s)
- Michael Spedding
- IUPHAR Secretary General, Spedding Research Solutions, 6 Rue Ampere, Le Vesinet, 78110, France
| | - Dinesh Kumar
- IPS President and Sr. Deputy Director, NIN (ICMR), New Delhi, India
| | - Bhagirath Patel
- IPS General Secretary and IUPHAR Executive Committee Member, AIIMS, New Delhi, India
| | - Y K Gupta
- Chairman IP-IP, Member, IUPS-IUPHAR National Committee and HOD Pharmacology, AIIMS, New Delhi, India E-mail:
| |
Collapse
|
43
|
Spedding M. Receptor nomenclature for publications in Indian journal of pharmacology. Indian J Pharmacol 2016. [PMCID: PMC4778202 DOI: 10.4103/0253-7613.174371] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
44
|
Spedding M. Receptor Nomenclature for Publications in Indian Journal of Pharmacology. Indian J Pharmacol 2016. [PMCID: PMC4899991 DOI: 10.4103/0253-7613.182899] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
45
|
Zohar J, Stahl S, Moller HJ, Blier P, Kupfer D, Yamawaki S, Uchida H, Spedding M, Goodwin GM, Nutt D. A review of the current nomenclature for psychotropic agents and an introduction to the Neuroscience-based Nomenclature. Eur Neuropsychopharmacol 2015; 25:2318-25. [PMID: 26527055 DOI: 10.1016/j.euroneuro.2015.08.019] [Citation(s) in RCA: 102] [Impact Index Per Article: 11.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/23/2015] [Revised: 08/20/2015] [Accepted: 08/27/2015] [Indexed: 01/04/2023]
Abstract
Neuroscience based Nomenclature (NbN) is a new system of classifying psychotropic drugs by their pharmacological profile. The NbN was developed to replace the current indication-based nomenclature and to provide an up-to-date and more useful framework to better inform pharmacological decisions. NbN provides updated relevant and specific scientific, regulatory and clinical information, aiming to support rational and lucid prescribing. This pharmacologically driven nomenclature, which highlights pharmacological domains and modes of action, may also increase drug adherence as it clarifies the rationale for selecting a specific psychotropic agent.
Collapse
Affiliation(s)
- Joseph Zohar
- Department of Psychiatry, Sheba Medical Center, and Sackler School of Medicine, Tel Aviv University , Tel Hashomer, Israel.
| | - Stephen Stahl
- Department of Psychiatry, University of California, San Diego, USA
| | - Hans-Jurgen Moller
- Department of Psychiatry and Psychotherapy, Ludwig-Maximilians-University, Munich, Germany
| | - Pierre Blier
- Department of Psychiatry and Cellular & Molecular Medicine, University of Ottawa, Canada K1Z 7K4
| | - David Kupfer
- Department of Psychiatry, University of Pittsburgh Medical Center, Pittsburgh, PA, USA
| | - Shigeto Yamawaki
- Department of Psychiatry and Neurosciences, Institute of Biomedical & Health Sciences, Hiroshima University, Hiroshima, Japan
| | - Hiroyuki Uchida
- Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan
| | - Michael Spedding
- Spedding Research Solutions SARL, 6 Rue Ampere, Le Vesinet 78110, France
| | - Guy M Goodwin
- University Department, Warneford Hospital, Oxford OX3 7JX , UK
| | - David Nutt
- Centre for Neuropsychopharmacology Division of Brain Sciences Imperial College, London, UK
| |
Collapse
|
46
|
Alexander SP, Kelly E, Marrion N, Peters JA, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Southan C, Buneman OP, Catterall WA, Cidlowski JA, Davenport AP, Fabbro D, Fan G, McGrath JC, Spedding M, Davies JA. The Concise Guide to PHARMACOLOGY 2015/16: Overview. Br J Pharmacol 2015; 172:5729-43. [PMID: 26650438 PMCID: PMC4718217 DOI: 10.1111/bph.13347] [Citation(s) in RCA: 215] [Impact Index Per Article: 23.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/04/2022] Open
Abstract
The Concise Guide to PHARMACOLOGY 2015/16 provides concise overviews of the key properties of over 1750 human drug targets with their pharmacology, plus links to an open access knowledgebase of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties. The full contents can be found at http://onlinelibrary.wiley.com/doi/10.1111/bph.13347/full. This compilation of the major pharmacological targets is divided into eight areas of focus: G protein-coupled receptors, ligand-gated ion channels, voltage-gated ion channels, other ion channels, nuclear hormone receptors, catalytic receptors, enzymes and transporters. These are presented with nomenclature guidance and summary information on the best available pharmacological tools, alongside key references and suggestions for further reading. The Concise Guide is published in landscape format in order to facilitate comparison of related targets. It is a condensed version of material contemporary to late 2015, which is presented in greater detail and constantly updated on the website www.guidetopharmacology.org, superseding data presented in the previous Guides to Receptors & Channels and the Concise Guide to PHARMACOLOGY 2013/14. It is produced in conjunction with NC-IUPHAR and provides the official IUPHAR classification and nomenclature for human drug targets, where appropriate. It consolidates information previously curated and displayed separately in IUPHAR-DB and GRAC and provides a permanent, citable, point-in-time record that will survive database updates.
Collapse
Affiliation(s)
- Stephen Ph Alexander
- School of Biomedical Sciences, University of Nottingham Medical School, Nottingham, NG7 2UH, UK
| | - Eamonn Kelly
- School of Physiology and Pharmacology, University of Bristol, Bristol, BS8 1TD, UK
| | - Neil Marrion
- School of Physiology and Pharmacology, University of Bristol, Bristol, BS8 1TD, UK
| | - John A Peters
- Neuroscience Division, Medical Education Institute, Ninewells Hospital and Medical School, University of Dundee, Dundee, DD1 9SY, UK
| | - Helen E Benson
- Centre for Integrative Physiology, University of Edinburgh, Edinburgh, EH8 9XD, UK
| | - Elena Faccenda
- Centre for Integrative Physiology, University of Edinburgh, Edinburgh, EH8 9XD, UK
| | - Adam J Pawson
- Centre for Integrative Physiology, University of Edinburgh, Edinburgh, EH8 9XD, UK
| | - Joanna L Sharman
- Centre for Integrative Physiology, University of Edinburgh, Edinburgh, EH8 9XD, UK
| | - Christopher Southan
- Centre for Integrative Physiology, University of Edinburgh, Edinburgh, EH8 9XD, UK
| | - O Peter Buneman
- Laboratory for Foundations of Computer Science, School of Informatics, University of Edinburgh, Edinburgh, EH8 9LE, United Kingdom
| | - William A Catterall
- Department of Pharmacology, University of Washington, Seattle, 98195-7280, WA, USA
| | - John A Cidlowski
- National Institute of Environmental Health Sciences, National Institutes of Health, Department of Health and Human Services, Research Triangle Park, 27709, NC, USA
| | | | | | - Grace Fan
- The Agnes Irwin School, Rosemont, Pennsylvania, USA
| | - John C McGrath
- School of Life Sciences, University of Glasgow, Glasgow, G12 8QQ, UK
| | | | - Jamie A Davies
- Centre for Integrative Physiology, University of Edinburgh, Edinburgh, EH8 9XD, UK
| |
Collapse
|
47
|
Grimm O, Gass N, Weber-Fahr W, Sartorius A, Schenker E, Spedding M, Risterucci C, Schweiger JI, Böhringer A, Zang Z, Tost H, Schwarz AJ, Meyer-Lindenberg A. Acute ketamine challenge increases resting state prefrontal-hippocampal connectivity in both humans and rats. Psychopharmacology (Berl) 2015; 232:4231-41. [PMID: 26184011 DOI: 10.1007/s00213-015-4022-y] [Citation(s) in RCA: 65] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/03/2015] [Accepted: 07/06/2015] [Indexed: 12/27/2022]
Abstract
RATIONALE Aberrant prefrontal-hippocampal (PFC-HC) connectivity is disrupted in several psychiatric and at-risk conditions. Advances in rodent functional imaging have opened the possibility that this phenotype could serve as a translational imaging marker for psychiatric research. Recent evidence from functional magnetic resonance imaging (fMRI) studies has indicated an increase in PFC-HC coupling during working-memory tasks in both schizophrenic patients and at-risk populations, in contrast to a decrease in resting-state PFC-HC connectivity. Acute ketamine challenge is widely used in both humans and rats as a pharmacological model to study the mechanisms of N-methyl-D-aspartate (NMDA) receptor hypofunction in the context of psychiatric disorders. OBJECTIVES We aimed to establish whether acute ketamine challenge has consistent effects in rats and humans by investigating resting-state fMRI PFC-HC connectivity and thus to corroborate its potential utility as a translational probe. METHODS Twenty-four healthy human subjects (12 females, mean age 25 years) received intravenous doses of either saline (placebo) or ketamine (0.5 mg/kg body weight). Eighteen Sprague-Dawley male rats received either saline or ketamine (25 mg/kg). Resting-state fMRI measurements took place after injections, and the data were analyzed for PFC-HC functional connectivity. RESULTS In both species, ketamine induced a robust increase in PFC-HC coupling, in contrast to findings in chronic schizophrenia. CONCLUSIONS This translational comparison demonstrates a cross-species consistency in pharmacological effect and elucidates ketamine-induced alterations in PFC-HC coupling, a phenotype often disrupted in pathological conditions, which may give clue to understanding of psychiatric disorders and their onset, and help in the development of new treatments.
Collapse
Affiliation(s)
- Oliver Grimm
- Department of Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, J5, 68159, Mannheim, Germany
| | - Natalia Gass
- Department of Neuroimaging, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, J5, 68159, Mannheim, Germany.
| | - Wolfgang Weber-Fahr
- Department of Neuroimaging, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, J5, 68159, Mannheim, Germany
| | - Alexander Sartorius
- Department of Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, J5, 68159, Mannheim, Germany.,Department of Neuroimaging, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, J5, 68159, Mannheim, Germany
| | - Esther Schenker
- Neuroscience Drug Discovery Unit, Institut de Recherches Servier, Croissy s/Seine, France
| | | | - Celine Risterucci
- CNS Biomarker, Pharmaceuticals Division, F. Hoffmann-La Roche, Basel, Switzerland
| | - Janina Isabel Schweiger
- Department of Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, J5, 68159, Mannheim, Germany
| | - Andreas Böhringer
- Department of Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, J5, 68159, Mannheim, Germany
| | - Zhenxiang Zang
- Department of Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, J5, 68159, Mannheim, Germany
| | - Heike Tost
- Department of Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, J5, 68159, Mannheim, Germany
| | - Adam James Schwarz
- Tailored Therapeutics, Eli Lilly and Company, Indianapolis, IN, USA.,Department of Psychological and Brain Sciences, Indiana University, Bloomington, IN, USA.,Department of Radiology and Imaging Sciences, Indiana University, Indianapolis, IN, USA
| | - Andreas Meyer-Lindenberg
- Department of Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, J5, 68159, Mannheim, Germany
| |
Collapse
|
48
|
Henriques A, Croixmarie V, Priestman DA, Rosenbohm A, Dirrig-Grosch S, D'Ambra E, Huebecker M, Hussain G, Boursier-Neyret C, Echaniz-Laguna A, Ludolph AC, Platt FM, Walther B, Spedding M, Loeffler JP, Gonzalez De Aguilar JL. Amyotrophic lateral sclerosis and denervation alter sphingolipids and up-regulate glucosylceramide synthase. Hum Mol Genet 2015; 24:7390-405. [PMID: 26483191 PMCID: PMC4664174 DOI: 10.1093/hmg/ddv439] [Citation(s) in RCA: 65] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2015] [Accepted: 10/12/2015] [Indexed: 02/05/2023] Open
Abstract
Amyotrophic lateral sclerosis (ALS) is a fatal adult-onset disease characterized by upper and lower motor neuron degeneration, muscle wasting and paralysis. Growing evidence suggests a link between changes in lipid metabolism and ALS. Here, we used UPLC/TOF-MS to survey the lipidome in SOD1(G86R) mice, a model of ALS. Significant changes in lipid expression were evident in spinal cord and skeletal muscle before overt neuropathology. In silico analysis also revealed appreciable changes in sphingolipids including ceramides and glucosylceramides (GlcCer). HPLC analysis showed increased amounts of GlcCer and downstream glycosphingolipids (GSLs) in SOD1(G86R) muscle compared with wild-type littermates. Glucosylceramide synthase (GCS), the enzyme responsible for GlcCer biosynthesis, was up-regulated in muscle of SOD1(G86R) mice and ALS patients, and in muscle of wild-type mice after surgically induced denervation. Conversely, inhibition of GCS in wild-type mice, following transient peripheral nerve injury, reversed the overexpression of genes in muscle involved in oxidative metabolism and delayed motor recovery. GCS inhibition in SOD1(G86R) mice also affected the expression of metabolic genes and induced a loss of muscle strength and morphological deterioration of the motor endplates. These findings suggest that GSLs may play a critical role in ALS muscle pathology and could lead to the identification of new therapeutic targets.
Collapse
Affiliation(s)
- Alexandre Henriques
- Université de Strasbourg, UMR_S 1118, Strasbourg, France, INSERM, U1118, Mécanismes Centraux et Péripheriques de la Neurodégénérescence, Strasbourg, France
| | | | | | | | - Sylvie Dirrig-Grosch
- Université de Strasbourg, UMR_S 1118, Strasbourg, France, INSERM, U1118, Mécanismes Centraux et Péripheriques de la Neurodégénérescence, Strasbourg, France
| | - Eleonora D'Ambra
- Université de Strasbourg, UMR_S 1118, Strasbourg, France, INSERM, U1118, Mécanismes Centraux et Péripheriques de la Neurodégénérescence, Strasbourg, France
| | | | - Ghulam Hussain
- Université de Strasbourg, UMR_S 1118, Strasbourg, France, INSERM, U1118, Mécanismes Centraux et Péripheriques de la Neurodégénérescence, Strasbourg, France, Department of Physiology, GC University, Faisalabad, Pakistan
| | | | - Andoni Echaniz-Laguna
- Université de Strasbourg, UMR_S 1118, Strasbourg, France, INSERM, U1118, Mécanismes Centraux et Péripheriques de la Neurodégénérescence, Strasbourg, France, Hôpitaux Universitaires, Département de Neurologie, Strasbourg, France
| | | | - Frances M Platt
- Department of Pharmacology, University of Oxford, Oxford, UK
| | | | - Michael Spedding
- Les Laboratoires Servier, Suresnes, France and Spedding Research Solutions SARL, Le Vesinet, France
| | - Jean-Philippe Loeffler
- Université de Strasbourg, UMR_S 1118, Strasbourg, France, INSERM, U1118, Mécanismes Centraux et Péripheriques de la Neurodégénérescence, Strasbourg, France
| | - Jose-Luis Gonzalez De Aguilar
- Université de Strasbourg, UMR_S 1118, Strasbourg, France, INSERM, U1118, Mécanismes Centraux et Péripheriques de la Neurodégénérescence, Strasbourg, France,
| |
Collapse
|
49
|
Southan C, Sharman JL, Benson HE, Faccenda E, Pawson AJ, Alexander SPH, Buneman OP, Davenport AP, McGrath JC, Peters JA, Spedding M, Catterall WA, Fabbro D, Davies JA. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. Nucleic Acids Res 2015; 44:D1054-68. [PMID: 26464438 PMCID: PMC4702778 DOI: 10.1093/nar/gkv1037] [Citation(s) in RCA: 1003] [Impact Index Per Article: 111.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/07/2015] [Accepted: 09/29/2015] [Indexed: 01/05/2023] Open
Abstract
The IUPHAR/BPS Guide to PHARMACOLOGY (GtoPdb, http://www.guidetopharmacology.org) provides expert-curated molecular interactions between successful and potential drugs and their targets in the human genome. Developed by the International Union of Basic and Clinical Pharmacology (IUPHAR) and the British Pharmacological Society (BPS), this resource, and its earlier incarnation as IUPHAR-DB, is described in our 2014 publication. This update incorporates changes over the intervening seven database releases. The unique model of content capture is based on established and new target class subcommittees collaborating with in-house curators. Most information comes from journal articles, but we now also index kinase cross-screening panels. Targets are specified by UniProtKB IDs. Small molecules are defined by PubChem Compound Identifiers (CIDs); ligand capture also includes peptides and clinical antibodies. We have extended the capture of ligands and targets linked via published quantitative binding data (e.g. Ki, IC50 or Kd). The resulting pharmacological relationship network now defines a data-supported druggable genome encompassing 7% of human proteins. The database also provides an expanded substrate for the biennially published compendium, the Concise Guide to PHARMACOLOGY. This article covers content increase, entity analysis, revised curation strategies, new website features and expanded download options.
Collapse
Affiliation(s)
- Christopher Southan
- Centre for Integrative Physiology, University of Edinburgh, Edinburgh, EH8 9XD, UK
| | - Joanna L Sharman
- Centre for Integrative Physiology, University of Edinburgh, Edinburgh, EH8 9XD, UK
| | - Helen E Benson
- Centre for Integrative Physiology, University of Edinburgh, Edinburgh, EH8 9XD, UK
| | - Elena Faccenda
- Centre for Integrative Physiology, University of Edinburgh, Edinburgh, EH8 9XD, UK
| | - Adam J Pawson
- Centre for Integrative Physiology, University of Edinburgh, Edinburgh, EH8 9XD, UK
| | - Stephen P H Alexander
- School of Biomedical Sciences, University of Nottingham Medical School, Nottingham, NG7 2UH, UK
| | - O Peter Buneman
- Laboratory for Foundations of Computer Science, School of Informatics, University of Edinburgh, Edinburgh, EH8 9LE, UK
| | | | - John C McGrath
- School of Life Sciences, University of Glasgow, Glasgow, G12 8QQ, UK
| | - John A Peters
- Neuroscience Division, Medical Education Institute, Ninewells Hospital and Medical School, University of Dundee, Dundee, DD1 9SY, UK
| | | | - William A Catterall
- Department of Pharmacology, University of Washington, Seattle, WA 98195-7280, USA
| | | | - Jamie A Davies
- Centre for Integrative Physiology, University of Edinburgh, Edinburgh, EH8 9XD, UK
| | | |
Collapse
|
50
|
Tiligada E, Ishii M, Riccardi C, Spedding M, Simon HU, Teixeira MM, Landys Chovel Cuervo M, Holgate ST, Levi-Schaffer F. The expanding role of immunopharmacology: IUPHAR Review 16. Br J Pharmacol 2015; 172:4217-27. [PMID: 26173913 PMCID: PMC4556463 DOI: 10.1111/bph.13219] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2015] [Revised: 05/05/2015] [Accepted: 05/20/2015] [Indexed: 02/06/2023] Open
Abstract
Drugs targeting the immune system such as corticosteroids, antihistamines and immunosuppressants have been widely exploited in the treatment of inflammatory, allergic and autoimmune disorders during the second half of the 20th century. The recent advances in immunopharmacological research have made available new classes of clinically relevant drugs. These comprise protein kinase inhibitors and biologics, such as monoclonal antibodies, that selectively modulate the immune response not only in cancer and autoimmunity but also in a number of other human pathologies. Likewise, more effective vaccines utilizing novel antigens and adjuvants are valuable tools for the prevention of transmissible infectious diseases and for allergen-specific immunotherapy. Consequently, immunopharmacology is presently considered as one of the expanding fields of pharmacology. Immunopharmacology addresses the selective regulation of immune responses and aims to uncover and exploit beneficial therapeutic options for typical and non-typical immune system-driven unmet clinical needs. While in the near future a number of new agents will be introduced, improving the effectiveness and safety of those currently in use is imperative for all researchers and clinicians working in the fields of immunology, pharmacology and drug discovery. The newly formed ImmuPhar (http://iuphar.us/index.php/sections-subcoms/immunopharmacology) is the Immunopharmacology Section of the International Union of Basic and Clinical Pharmacology (IUPHAR, http://iuphar.us/). ImmuPhar provides a unique international expert-lead platform that aims to dissect and promote the growing understanding of immune (patho)physiology. Moreover, it challenges the identification and validation of drug targets and lead candidates for the treatment of many forms of debilitating disorders, including, among others, cancer, allergies, autoimmune and metabolic diseases.
Collapse
Affiliation(s)
- Ekaterini Tiligada
- Department of Pharmacology, Medical School, University of AthensAthens, Greece
- Allergy Unit ‘D. Kalogeromitros’, 2nd Department of Dermatology and Venereology, ‘Attikon’ General University Hospital, Medical School, University of AthensAthens, Greece
| | - Masaru Ishii
- Department of Immunology and Cell Biology, Graduate School of Medicine and Frontier Biosciences, Osaka UniversityOsaka, Japan
| | - Carlo Riccardi
- Department of Medicine, University of PerugiaPerugia, Italy
| | | | - Hans-Uwe Simon
- Institute of Pharmacology, University of BernBern, Switzerland
| | | | | | | | - Francesca Levi-Schaffer
- Pharmacology Unit, Faculty of Medicine, School of Pharmacy Institute for Drug Research, Hebrew University of JerusalemJerusalem, Israel
| |
Collapse
|